The storylines故事线
Click a development’s source links to open the original article.点击进展下方的来源链接可打开原文。
Annual & quarterly financial results年度及季度财务业绩
53 · 2024-01-08 → 2026-08-03
▾
Recurring reporting of annual, semi-annual, and quarterly financial performance.定期报告年度、半年度和季度财务业绩。
2024-01-08WuXi AppTec attended the 42nd J.P. Morgan Annual Healthcare Conference and gave a keynote speech, highlighting its CRDMO and CTDMO business models serving over 6,000 partners in 30+ countries.药明康德出席第42届摩根大通年度医疗健康大会并发表主题演讲，介绍其CRDMO和CTDMO业务模式，服务全球30多个国家6000多家合作伙伴。
2024-01-11WuXi AppTec stated that driven by its CRDMO model, it expects 2023 annual revenue, profit, and free cash flow to hit record highs.药明康德表示，在CRDMO业务模式驱动下，预计2023年度营收、利润及自由现金流均将创下历史新高。
2024-02-08WuXi AppTec reiterates 2023 guidance: full-year revenue to exceed CNY 40 billion, adjusted non-IFRS net profit to exceed CNY 10 billion for the first time, and free cash flow over CNY 4.5 billion.药明康德重申2023年业绩指引：全年营收突破400亿元，经调整non-IFRS归母净利润首次突破百亿，自由现金流超过45亿元。
2024-03-18WuXi AppTec reported FY2023 revenue of RMB 40.341 billion (+2.5% YoY; +25.6% ex-COVID), net profit of RMB 9.607 billion (+9% YoY). Proposed final dividend of RMB 0.98336 per share, total payout ~RMB 2.882 billion (30% payout ratio).药明康德发布2023年年报：营收403.41亿元（同比+2.5%，剔除新冠项目+25.6%），净利润96.07亿元（同比+9%）。拟每10股派发现金红利9.8336元，合计约28.82亿元（分红率30%）。
2024-03-18WuXi AppTec guided FY2024 revenue of RMB 38.3-40.5 billion, ex-COVID growth of 2.7-8.6%; expects 2024 free cash flow of RMB 4-5 billion and capex of ~RMB 5 billion.药明康德预计2024年收入383-405亿元，剔除新冠项目后增长2.7-8.6%；预计2024年自由现金流40-50亿元，资本开支约50亿元。
2024-04-29Q1 2024 revenue RMB 7.982 billion, down 10.95% YoY; net profit RMB 1.942 billion, down 10.42% YoY; ex-COVID commercial projects revenue down 1.8% YoY; full-year 2024 revenue guidance RMB 38.3-40.5 billion.2024年一季度营收79.82亿元，同比下降10.95%；净利润19.42亿元，同比下降10.42%；剔除新冠商业化项目收入同比下降1.8%；2024全年收入指引383-405亿元。
2024-04-29Q1 2024 net profit attributable to shareholders RMB 1.942 billion, down 10.42% YoY; non-GAAP adjusted net profit RMB 1.913 billion; free cash flow RMB 1.326 billion; full-year 2024 free cash flow guidance RMB 4.0-5.0 billion.2024年一季度归母净利润19.42亿元，同比下降10.42%；经调整Non-IFRS归母净利润19.13亿元；自由现金流13.26亿元；2024全年自由现金流指引40-50亿元。
2024-05-06WuXi AppTec reported Q1 2024 revenue of RMB 7.982 billion, down 10.95% YoY; net profit attributable to shareholders of RMB 1.942 billion, down 10.42% YoY; excluding COVID-19 commercial projects, revenue fell 1.8% YoY.药明康德公布2024年一季度营收79.82亿元，同比下降10.95%；归母净利润19.42亿元，同比下降10.42%；剔除新冠商业化项目后收入同比下降1.8%。
2024-06-28WuXi AppTec guided that H1 2024 revenue is expected to account for 42%-45% of full-year revenue, based on current delivery schedules and Q2 project scale.药明康德预计2024年上半年收入将占到全年的42%-45%左右，基于当前交付时间和二季度项目规模。
2024-07-29WuXi AppTec reported 2024 H1 revenue of RMB 17.241 billion, down 8.64% YoY; net profit of RMB 4.24 billion, down 20.20% YoY. Excluding specific commercial production projects, revenue was roughly flat. Q2 revenue was RMB 9.259 billion, up 16% QoQ; adjusted non-IFRS net profit was RMB 2.46 billion, up 28.5% QoQ.药明康德公布2024年上半年营收172.41亿元，同比下降8.64%；净利润42.4亿元，同比下降20.20%。剔除特定商业化生产项目后营收基本持平。二季度营收92.59亿元，环比增长16%；经调整non-IFRS净利润24.6亿元，环比增长28.5%。
2024-07-29WuXi AppTec maintained its 2024 full-year guidance: revenue of RMB 383-405 billion, excluding specific commercial production projects, positive growth of 2.7%-8.6%; free cash flow of RMB 4-5 billion; adjusted non-IFRS net profit margin roughly flat with last year.药明康德维持2024年全年指引：收入383-405亿元，剔除特定商业化生产项目后保持正增长（2.7%-8.6%）；自由现金流40-50亿元；经调整non-IFRS归母净利率与去年相当。
2024-08-01WUXI APPTEC released 2024 semi-annual report: revenue 17.241 billion yuan, down 8.64% YoY; net profit 4.24 billion yuan, down 20.20% YoY; first mid-year revenue and net profit decline since listing.药明康德发布2024年半年报：营业收入172.41亿元，同比下降8.64%；净利润42.40亿元，同比下降20.20%；上市以来首次中报营收和净利润双降。
2024-08-01WUXI APPTEC's Q2 2024 revenue was 9.259 billion yuan, up 16.0% QoQ; net profit was 2.297 billion yuan, up 18.31% QoQ.药明康德2024年第二季度营业收入92.59亿元，环比增长16.0%；净利润22.97亿元，环比增长18.31%。
2024-08-01WUXI APPTEC maintained its 2024 full-year guidance: revenue 38.3-40.5 billion yuan, excluding COVID-19 commercial projects revenue growth of 2.7%-8.6%.药明康德维持2024全年业绩指引：营收383-405亿元，剔除新冠商业化项目后营收增长2.7%-8.6%。
2024-08-22WUXI APPTEC announced its 2024 semi-annual results briefing will be held on August 30, 2024, via online video and Q&A.药明康德宣布2024年半年度业绩说明会将于2024年8月30日以线上视频和互动形式举行。
2024-10-28WuXi AppTec reports Q3 2024 revenue of RMB 10.461 billion (-1.96% YoY), net profit of RMB 2.293 billion (-17.02% YoY); 9M 2024 revenue of RMB 27.702 billion (-6.23% YoY), net profit of RMB 6.533 billion (-19.11% YoY). Order backlog reaches a record RMB 43.82 billion, +35.2% YoY.药明康德2024年第三季度营收104.61亿元（同比-1.96%），净利润22.93亿元（同比-17.02%）；前三季度营收277.02亿元（同比-6.23%），净利润65.33亿元（同比-19.11%）。在手订单达创纪录的438.2亿元，同比增长35.2%。
2024-10-28WuXi AppTec reaffirms FY2024 guidance: revenue RMB 38.3-40.5 billion, free cash flow RMB 6-7 billion, adjusted non-IFRS net profit margin similar to prior year.药明康德重申2024年业绩指引：全年收入383-405亿元，自由现金流60-70亿元，经调整non-IFRS归母净利率与去年相当。
2024-11-01Q3 2024 revenue reached 10.461 billion yuan, up 14.6% YoY excluding COVID projects; new customers exceeded 800 in first three quarters; orders in hand reached 43.82 billion yuan, up 35.2% YoY.2024年第三季度收入104.61亿元，剔除新冠项目同比增长14.6%；前三季度新增客户超800家；在手订单438.2亿元，同比增长35.2%。
2025-03-17FY2024 revenue RMB 39.241B (-2.73% YoY); net profit RMB 9.45B (-1.63% YoY); ex-COVID commercial projects revenue +5.2% YoY; Q4 revenue RMB 11.539B and adjusted net profit both hit record highs.2024年全年营收392.41亿元（同比-2.73%）；归母净利润94.50亿元（同比-1.63%）；剔除新冠商业化项目营收同比+5.2%；第四季度营收115.39亿元及经调整净利润均创历史新高。
2025-03-17FY2024 adjusted non-IFRS net profit RMB 10.58B, -2.5% YoY; adjusted non-IFRS net margin 27.0%, a record high; free cash flow reached a record high of RMB 7.98B.2024年经调整non-IFRS归母净利润105.8亿元，同比-2.5%；经调整non-IFRS净利率27.0%，创历史新高；自由现金流达79.8亿元，创历史新高。
2025-03-17FY2024 net cash flow from operations RMB 12.407B; total assets RMB 80.326B (+9.04% YoY); debt-to-asset ratio 26.44%.2024年经营性现金流124.07亿元；总资产803.26亿元（同比+9.04%）；资产负债率26.44%。
2025-03-17FY2024 gross margin 41.48%, +0.30 ppts YoY; net margin 24.38%, +1.4 ppts YoY.2024年毛利率41.48%，同比+0.30个百分点；净利率24.38%，同比+1.4个百分点。
2025-04-01WuXi AppTec reported 2024 full-year revenue of RMB 39.241 billion, adjusted non-IFRS net profit of RMB 10.583 billion, and record free cash flow of nearly RMB 8 billion.药明康德发布2024年业绩：营业收入392.41亿元，经调整non-IFRS归母净利润105.83亿元，自由现金流近80亿元创历史新高。
2025-04-28WuXi AppTec reported Q1 2025 revenue of RMB 9.655 billion (+20.96% YoY) and net profit of RMB 3.672 billion (+89.06% YoY).药明康德2025年一季度营业收入96.55亿元（同比+20.96%），净利润36.72亿元（同比+89.06%）。
2025-05-06Q1 2025 revenue up 21% YoY to RMB 9.655 billion; net profit up 89.1% to RMB 3.672 billion; adjusted non-IFRS net profit up 40% to RMB 2.68 billion; orders in hand for continuing operations up 47.1% to RMB 52.33 billion.2025年第一季度收入同比增长21%至96.55亿元；净利润增长89.1%至36.72亿元；经调整non-IFRS净利润增长40%至26.8亿元；持续经营业务在手订单增长47.1%至523.3亿元。
2025-06-30WuXi AppTec's Q1 2025 revenue reached RMB 9.655 billion (+21.0% YoY), net profit RMB 3.672 billion (+89.06% YoY), driven by Chemistry (+32.9%) and TIDES (+187.6% to RMB 2.24 billion).药明康德2025年一季度营收96.55亿元（同比+21.0%），净利润36.72亿元（同比+89.06%），化学业务（+32.9%）和TIDES业务（+187.6%至22.4亿元）驱动增长。
2025-07-10Announced H1 2025 results: revenue ~RMB 20.799B (+20.64% YoY), adjusted net profit ~RMB 6.315B (+44.43% YoY), net profit ~RMB 8.561B (+101.92% YoY) including ~RMB 3.21B gain from selling part of WuXi XDC Cayman Inc. shares.发布2025年上半年业绩：营收约207.99亿元（同比+20.64%），经调整归母净利润约63.15亿元（同比+44.43%），归母净利润约85.61亿元（同比+101.92%），其中包含出售药明合联部分股票收益约32.1亿元。
2025-07-28Raised 2025 full-year guidance: continuing ops revenue growth from 10-15% to 13-17%, total revenue from RMB 41.5-43B to RMB 42.5-43.5B, free cash flow from RMB 4-5B to RMB 5-6B.上调2025年全年指引：持续经营业务收入增速从10-15%上调至13-17%，整体收入从415-430亿元上调至425-435亿元，自由现金流从40-50亿元上调至50-60亿元。
2025-07-28WuXi AppTec reported H1 2025 revenue of RMB 20.8 billion (+20.6% YoY), net profit attributable to shareholders of RMB 8.561 billion (+101.9% YoY), and raised its full-year 2025 revenue guidance to RMB 42.5-43.5 billion (from RMB 41.5-43.0 billion), with continuing operations expected to grow 13-17%.药明康德发布2025年半年报：营收208亿元（同比+20.6%），归母净利润85.61亿元（同比+101.9%），上调全年收入指引至425-435亿元（此前为415-430亿元），持续经营业务预计增长13-17%。
2025-09-05WuXi AppTec disclosed in its 2025 semi-annual report that continuing operations revenue exceeded 20.4B RMB (+24.2% YoY), and adjusted non-IFRS net profit reached 6.31B RMB (+44.4% YoY).药明康德2025年半年报显示，持续经营业务收入超204亿元（同比增长24.2%），经调整non-IFRS净利润达63.1亿元（同比增长44.4%）。
2025-10-26Q3 2025 revenue RMB 12.057 billion, +15.26% YoY; net profit RMB 3.515 billion, +53.27% YoY. 9M 2025 revenue RMB 32.857 billion, +18.61% YoY; net profit RMB 12.076 billion, +84.84% YoY. Raised full-year revenue guidance to RMB 43.5-44.0 billion (from RMB 42.5-43.5 billion), with continuing ops growth of 17-18%.2025年第三季度营收120.57亿元，同比增长15.26%；净利润35.15亿元，同比增长53.27%。前三季度营收328.57亿元，同比增长18.61%；净利润120.76亿元，同比增长84.84%。全年营收指引上调至435-440亿元（此前为425-435亿元），持续经营业务增速17-18%。
2025-10-26Full-year free cash flow guidance raised to RMB 8.0-8.5 billion (from RMB 5.0-6.0 billion); full-year capex budget lowered to RMB 5.5-6.0 billion (from RMB 7.0-8.0 billion).全年自由现金流指引上调至80-85亿元（此前为50-60亿元）；全年资本支出预算下调至55-60亿元（此前为70-80亿元）。
2025-10-26Q3 2025 gross margin reached 46.62%, a five-year quarterly high.2025年第三季度毛利率达46.62%，创近五年单季新高。
2025-11-07Raised 2025 continuing operations revenue guidance for the second time: from RMB 42.5-43.5 billion (13-17% growth) to RMB 43.5-44.0 billion (17-18% growth).年内第二次上调2025年持续经营业务收入指引：从425-435亿元（增速13-17%）上调至435-440亿元（增速17-18%）。
2026-01-12Announced 2025 preliminary results: revenue ~45.46 billion yuan (+15.84% YoY), continuing ops revenue +21.4%; adjusted net profit ~14.96 billion yuan (+41.33%); net profit ~19.15 billion yuan (+102.65%); EPS ~6.70 yuan (+104.27%).发布2025年度业绩预增公告：预计营业收入约454.56亿元（同比+15.84%），持续经营业务收入同比+21.4%；经调整归母净利润约149.57亿元（+41.33%）；归母净利润约191.51亿元（+102.65%）；基本每股收益约6.70元（+104.27%）。
2026-03-23FY2025 revenue RMB 45.456B, +15.8% YoY; net profit RMB 19.151B, +102.65% YoY; proposed final dividend RMB 1.57927 per 10 shares, total ~RMB 4.712B.2025年全年营收454.56亿元，同比增长15.8%；归母净利润191.51亿元，同比增长102.65%；拟每10股派发现金红利15.7927元，合计约47.12亿元。
2026-03-23FY2025 adjusted operating cash flow RMB 16.67B, +39.1% YoY; total assets exceeded RMB 100B for the first time.2025年经调整经营现金流166.7亿元，同比增长39.1%；总资产首次突破1000亿元。
2026-03-23FY2025 gross margin 47.64%, +6.16pp YoY; net margin 42.53%, +18.15pp YoY.2025年毛利率47.64%，同比上升6.16个百分点；净利率42.53%，同比上升18.15个百分点。
2026-04-03WuXi AppTec released its 2025 annual report: full-year revenue was 45.456 billion yuan, up 15.84% YoY; net profit was 19.151 billion yuan, up 102.65% YoY. Total employees were 33,834, a decrease of 5,580 from the end of the previous year.药明康德发布2025年年报：全年营收454.56亿元，同比增长15.84%；净利润191.51亿元，同比增长102.65%。在职员工总数33834人，较上年末减少5580人。
2026-04-27WuXi AppTec released its Q1 2026 results: revenue was 12.436 billion yuan, up 28.81% YoY; net profit was 4.652 billion yuan, up 26.68% YoY. Revenue from continuing operations grew 39.4% YoY.药明康德发布2026年一季报：营收124.36亿元，同比增长28.81%；净利润46.52亿元，同比增长26.68%。持续经营业务收入同比增长39.4%。
2026-04-27WuXi AppTec maintained its full-year 2026 guidance: total revenue of 51.3 to 53 billion yuan, continuing operations revenue growth of 18-22% YoY. It also guided for 2026 capital expenditure of 6.5 to 7.5 billion yuan.药明康德维持2026年全年业绩指引：整体收入513亿元至530亿元，持续经营业务收入同比增长18-22%。预计2026年资本开支65-75亿元。
2026-04-27WuXi AppTec's Q1 2026 adjusted non-IFRS gross margin reached 50.4%, a record high for a single quarter since listing. Adjusted non-IFRS net profit margin reached 37.0%.药明康德2026年第一季度经调整non-IFRS毛利率达到50.4%，为上市以来首次单季度毛利率突破50%。经调整non-IFRS归母净利率达到37.0%。
2026-05-01Released 2026 Q1 report: revenue RMB 12.436 billion, +28.81% YoY; net profit RMB 4.652 billion, +26.68% YoY; first quarterly revenue above RMB 10 billion.发布2026年一季报：营收124.36亿元，同比增长28.81%；归母净利润46.52亿元，同比增长26.68%；单季营收首次突破百亿元。
2026-08-03Reported H1 2026 revenue of RMB 28.897 billion (+38.93% YoY), net profit of RMB 11.08 billion (+29.43% YoY), and adjusted non-IFRS net profit of RMB 11.57 billion (+83.2% YoY).公布2026年上半年营收288.97亿元（同比+38.93%），净利润110.8亿元（同比+29.43%），经调整non-IFRS净利润115.7亿元（同比+83.2%）。
2026-08-03Raised full-year 2026 revenue guidance to RMB 58.5-60.5 billion (from RMB 51.3-53.0 billion), implying 35%-39% growth for continuing operations; raised capex guidance to RMB 7.5-8.5 billion and adjusted FCF to RMB 13.5-14.5 billion.将2026年全年收入指引上调至585-605亿元（原为513-530亿元），持续经营业务增速上调至35%-39%；资本开支指引上调至75-85亿元，经调整自由现金流上调至135-145亿元。
2026-08-03H1 2026 operating cash flow reached RMB 9.699 billion, up 30.5% YoY; accounts receivable rose 44.19% to RMB 10.472 billion, exceeding revenue growth.2026年上半年经营现金流净额96.99亿元，同比增长30.5%；应收账款增长44.19%至104.72亿元，增速超过营收。
2026-08-03H1 2026 gross margin improved 9.46 ppts YoY to 53.91%; adjusted non-IFRS net margin rose 9.7 ppts to 40.0%.2026年上半年毛利率同比提升9.46个百分点至53.91%；经调整non-IFRS净利率提升9.7个百分点至40.0%。
2026-08-03H1 2026 net profit attributable to shareholders excluding non-recurring items rose 89.39% YoY to RMB 10.572 billion, driven by strong core business growth.2026年上半年扣非归母净利润105.72亿元，同比增长89.39%，主要受核心业务强劲增长驱动。
2026-08-03H1 2026 Q2 revenue hit record RMB 16.462 billion, up 47.71% YoY; Q2 adjusted non-IFRS net profit rose 91.7% YoY.2026年第二季度营收164.62亿元，创单季历史新高，同比增长47.71%；经调整non-IFRS净利润同比增长91.7%。
2026-08-03H1 2026 revenue from continuing operations grew 48% YoY; Q2 continuing operations revenue grew 55.2% YoY.2026年上半年持续经营业务收入同比增长48%；第二季度持续经营业务收入同比增长55.2%。
2026-08-03H1 2026 net profit attributable to shareholders excluding non-recurring items rose 89.39% YoY to RMB 10.572 billion, driven by strong core business growth.2026年上半年扣非归母净利润105.72亿元，同比增长89.39%，主要受核心业务强劲增长驱动。
2026-08-03H1 2026 Q2 revenue hit record RMB 16.462 billion, up 47.71% YoY; Q2 adjusted non-IFRS net profit rose 91.7% YoY.2026年第二季度营收164.62亿元，创单季历史新高，同比增长47.71%；经调整non-IFRS净利润同比增长91.7%。
2026-08-03H1 2026 revenue from continuing operations grew 48% YoY; Q2 continuing operations revenue grew 55.2% YoY.2026年上半年持续经营业务收入同比增长48%；第二季度持续经营业务收入同比增长55.2%。
TIDES (peptide & oligonucleotide) expansionTIDES（多肽与寡核苷酸）扩张
33 · 2024-01-09 → 2026-08-03
▾
Rapid growth and capacity expansion of the TIDES business, driven by GLP-1 and oligonucleotide demand.在GLP-1和寡核苷酸需求驱动下，TIDES业务的快速增长和产能扩张。
2024-01-09WuXi AppTec announced the commissioning of new peptide production workshops in Changzhou and Taixing, Jiangsu, increasing total solid-phase synthesis vessel volume to 32,000L.药明康德宣布其位于江苏常州及泰兴的多肽生产车间正式投产，多肽固相合成釜总体积提升至32,000L。
2024-03-18WuXi AppTec's TIDES (oligonucleotide and peptide) revenue reached RMB 3.41 billion in 2023, up 64.4% YoY; new peptide solid-phase synthesis capacity expanded to 32,000L with new plants in Changzhou and Taixing operational since Jan 2024.药明康德2023年TIDES（寡核苷酸和多肽）业务收入34.1亿元，同比增长64.4%；多肽固相合成釜总容积扩至3.2万升，常州和泰兴新产能已于2024年1月投产。
2024-04-29TIDES (oligonucleotide and peptide) business Q1 2024 revenue RMB 780 million, up 43.1% YoY; TIDES orders in hand up 110% YoY at end of Q1; peptide solid-phase synthesis reactor volume increased to 32,000 L in Jan 2024.TIDES（寡核苷酸和多肽）业务2024年一季度收入7.8亿元，同比增长43.1%；一季度末在手订单同比增长110%；2024年1月多肽固相合成反应釜体积增加至32,000升。
2024-04-3022,000 L new peptide capacity fully put into use in Jan 2024, currently undergoing PPQ process validation batches; planning to expand new peptide capacity in Taixing.2024年1月22,000升多肽新产能已全部投入使用，正在进行PPQ工艺验证批次；计划在泰兴扩建新的多肽产能。
2024-07-29WuXi AppTec's TIDES business (peptides and oligonucleotides) revenue was RMB 2.08 billion in H1 2024, up 57.2% YoY. Orders in hand for TIDES grew 147% YoY. The company expects TIDES revenue to grow over 60% for the full year 2024.药明康德TIDES业务（多肽和寡核苷酸）2024年上半年收入20.8亿元，同比增长57.2%。TIDES在手订单同比增长147%。公司预计2024年全年TIDES收入增长超60%。
2024-07-29WuXi AppTec's peptide solid-phase synthesis reactor capacity increased to 32,000 L as of January 2024. The company plans to further expand peptide capacity, which will be a key growth engine.截至2024年1月，药明康德多肽固相合成反应釜总体积增加至32,000升。公司计划进一步扩大多肽产能，将其作为未来重要增长引擎。
2024-08-01WUXI APPTEC's TIDES business (oligonucleotides and peptides) revenue in H1 2024 was 2.08 billion yuan, up 57.2% YoY.药明康德TIDES业务（寡核苷酸和多肽）2024年上半年收入20.8亿元，同比增长57.2%。
2024-08-01WUXI APPTEC increased total volume of peptide solid-phase synthesis reactors to 32,000 L in January 2024.药明康德于2024年1月将多肽固相合成反应釜总体积增加至32,000升。
2024-09-27WuXi AppTec's TIDES business (oligonucleotides, peptides, conjugates) is accelerating; the company reduced PMO drug active ingredient cost by 60% over 3 years and enabled one PPMO therapy from API to IND in 11 months.药明康德TIDES业务（寡核苷酸、多肽、偶联物）加速发展；公司在3年内将PMO类药物活性成分成本降低60%，并助力一款PPMO疗法从API开发到IND仅耗时11个月。
2024-10-28WuXi AppTec's TIDES business (oligonucleotides and peptides) achieves 9M 2024 revenue of RMB 3.55 billion, +71% YoY; full-year TIDES revenue growth expected to exceed 60%. Solid-phase peptide synthesis reactor volume increased to 32,000 L in Jan 2024, targeting 41,000 L by end of 2024.药明康德TIDES业务（寡核苷酸和多肽）2024年前三季度收入35.5亿元，同比增长71%；预计全年TIDES收入增速超60%。多肽固相合成反应釜体积2024年1月增至32000L，目标2024年底达41000L。
2024-11-01Peptide solid-phase synthesis reactor total volume increased to 32,000L as of January 2024; Taixing base to reach 100,000L+ after full completion (2025 and beyond).截至2024年1月，多肽固相合成反应釜总体积增至32,000L；泰兴基地全部建成后（2025年及以后）将达到100,000L+。
2024-11-18TIDES business revenue reached 3.55 billion yuan in first three quarters, up 71.0% YoY; orders in hand surged 196% YoY; DM customer count up 20%, molecular count up 22%; full-year growth expected over 60%.TIDES业务前三季度收入35.5亿元，同比增长71.0%；在手订单激增196%；DM客户数增长20%，分子数增长22%；全年增长预计超60%。
2024-11-18Peptide solid-phase synthesis reactor total volume expected to increase to 41,000L by end of 2024, up from 32,000L in January 2024.多肽固相合成反应釜总体积预计2024年底进一步增至41,000L，高于2024年1月的32,000L。
2025-01-15At JPM, disclosed that TIDES solid-phase peptide synthesis reactor capacity reached 41,000L by end-2024, targeting >100,000L by end-2025.在JPM大会上披露，TIDES多肽固相合成反应釜产能截至2024年末达41000升，预计2025年末超过100000升。
2025-03-17FY2024 TIDES (oligonucleotide & peptide) revenue RMB 5.8B, +70.1% YoY, exceeding the 60% growth guidance; peptide solid-phase synthesis reactor total volume reached 41,000L by end-2024, expected to exceed 100,000L by end-2025.2024年TIDES（寡核苷酸和多肽）业务收入58亿元，同比+70.1%，超出全年60%增速指引；多肽固相合成反应釜总体积2024年底达4.1万升，预计2025年底超10万升。
2025-03-18At the 2024 results call, management guided TIDES revenue growth of over 60% for 2025; noted over 20 GLP-1 project pipelines on the platform, representing >20% of global market share.在2024年业绩电话会上，管理层预计2025年TIDES收入增长超60%；平台上有超过20个GLP-1项目管线，占全球市场份额20%以上。
2025-04-28WuXi AppTec's TIDES business Q1 2025 revenue reached RMB 2.24 billion (+187.6% YoY); solid-phase synthesis reactor capacity at Taixing to exceed 100,000 L by end-2025.药明康德TIDES业务一季度收入22.4亿元（同比+187.6%），泰兴多肽固相合成反应釜总体积预计2025年底超10万升。
2025-05-15TIDES business Q1 2025 revenue reached RMB 2.24 billion, up 187.6% YoY; TIDES orders in hand up 105.5% YoY; Taixing multi-peptide capacity expansion ongoing, with solid-phase synthesis reactor volume expected to exceed 100,000 L by end of 2025.TIDES业务2025年第一季度收入达22.4亿元，同比增长187.6%；在手订单同比增长105.5%；泰兴多肽产能持续扩张，预计2025年末多肽固相合成反应釜总体积超10万升。
2025-07-28H1 2025 TIDES (oligonucleotide & peptide) revenue reached RMB 5.03B, +141.6% YoY; TIDES order backlog +48.8% YoY; plans to expand solid-phase peptide synthesis capacity to >100,000L by end of 2025.2025年上半年TIDES（寡核苷酸和多肽）业务收入达50.3亿元，同比增长141.6%；在手订单同比增长48.8%；计划2025年底将多肽固相合成反应釜总体积提升至超10万升。
2025-07-28WuXi AppTec's TIDES business (peptides and oligonucleotides) achieved H1 2025 revenue of RMB 5.03 billion, up 141.6% YoY; the company expects total peptide solid-phase synthesis reactor volume to exceed 100,000 L by end of 2025.药明康德TIDES业务（多肽和寡核苷酸）2025年上半年收入50.3亿元，同比增长141.6%；预计2025年底多肽固相合成反应釜总体积将超过10万升。
2025-10-26As of Sep 30, 2025, small-molecule CDMO pipeline reached 80 commercial-stage molecules; small-molecule API reactor total volume expected to exceed 4,000 kL by end of 2025. TIDES revenue in 9M 2025 was RMB 7.84 billion, +121.1% YoY.截至2025年9月30日，小分子CDMO管线商业化分子达80个；预计2025年底小分子原料药反应釜总体积超400万升。前三季度TIDES收入78.4亿元，同比增长121.1%。
2025-11-03Completed Taixing (泰兴) peptide capacity expansion ahead of schedule; total solid-phase synthesis reactor volume exceeded 100,000 L by end of September 2025 (original target was year-end).提前完成泰兴多肽产能建设；截至2025年9月底，多肽固相合成反应釜总体积突破10万升（原计划年底达成）。
2026-01-14At JPM conference, disclosed supporting 24 GLP-1 drugs (small molecule and peptide), with 15 in phase II/III trials; TIDES revenue grew >90% in 2025, expected to exceed 11 billion yuan.在JPM大会上披露，正在支持24款GLP-1药物（小分子和多肽），其中15款进入二期/三期临床；TIDES业务2025年收入增长超90%，预计突破110亿元。
2026-03-23FY2025 continuing operations orders on hand reached RMB 58.0B, +28.8% YoY; TIDES revenue RMB 11.37B, +96.0% YoY.2025年末持续经营业务在手订单580亿元，同比增长28.8%；TIDES业务收入113.7亿元，同比增长96.0%。
2026-03-23FY2025 chemistry revenue RMB 36.47B, +25.5% YoY; TIDES revenue RMB 11.37B, +96.0% YoY; TIDES orders on hand +20.2% YoY.2025年化学业务收入364.7亿元，同比增长25.5%；TIDES业务收入113.7亿元，同比增长96.0%；TIDES在手订单同比增长20.2%。
2026-04-20WuXi AppTec's TIDES (peptide and oligonucleotide) business achieved revenue of 11.37 billion yuan in 2025, a YoY increase of 96.0%, with orders in hand growing 20.2%.药明康德TIDES（多肽与寡核苷酸）业务2025年实现收入113.7亿元，同比大增96.0%，在手订单增长20.2%。
2026-04-27WuXi AppTec's TIDES business revenue in Q1 2026 was 2.38 billion yuan, up 6.1% YoY. The company expects full-year TIDES revenue growth of about 40%, with scale exceeding 15 billion yuan.药明康德2026年第一季度TIDES业务收入23.8亿元，同比增长6.1%。公司预计全年TIDES业务收入增长约40%，规模将超150亿元。
2026-05-01Q1 small molecule DM revenue RMB 6.93 billion, +80.1% YoY; TIDES revenue RMB 2.38 billion; solid-phase synthesis reactor capacity exceeded 100,000 L, targeting 130,000 L.一季度小分子DM收入69.3亿元，同比增长80.1%；TIDES收入23.8亿元；多肽固相合成反应釜总体积突破10万升，目标13万升。
2026-07-10WUXI APPTEC's solid-phase peptide synthesis reactors exceeded 100,000 L in Q3 2025 and will expand to 130,000 L in 2026, with 3 new workshops to be commissioned.药明康德多肽固相合成反应釜在2025年三季度突破10万升，2026年将扩容至13万升，同步推进3个新车间投产。
2026-07-17WUXI APPTEC's TIDES business is driven by GLP-1 and oligonucleotide high景气, becoming the second growth curve; total orders in hand reached 597.7 billion yuan as of Q1 2026, up 23.6% YoY.药明康德TIDES业务受益于GLP-1和寡核苷酸高景气成为第二增长曲线；截至2026年一季度在手订单597.7亿元，同比增长23.6%。
2026-08-03H1 2026 TIDES (oligonucleotide and peptide) revenue reached RMB 7.26 billion, up 44.3% YoY; raised full-year TIDES growth guidance to ~45%.2026年上半年TIDES（寡核苷酸和多肽）业务收入72.6亿元，同比增长44.3%；将全年TIDES收入增速指引上调至约45%。
2026-08-03H1 2026 TIDES business customer count and molecule count grew 39% and 68% respectively; TIDES capacity expanded to 130,000 liters.2026年上半年TIDES业务客户数增长39%，服务分子数增长68%；TIDES产能扩张至13万升。
2026-08-03H1 2026 TIDES business customer count and molecule count grew 39% and 68% respectively; TIDES capacity expanded to 130,000 liters.2026年上半年TIDES业务客户数增长39%，服务分子数增长68%；TIDES产能扩张至13万升。
Taixing & Changzhou API base buildout泰兴与常州原料药基地建设
3 · 2024-01-09 → 2025-08-07
▾
Development and FDA inspection success of the Taixing and Changzhou API production bases.泰兴和常州原料药生产基地的开发及通过FDA检查。
2024-01-09WuXi AppTec's new Taixing API production base, the largest among its five API sites covering 684,000 sqm, began operations; Phase I expected fully operational by 2025, with total reactor volume exceeding 4,000 cubic meters.药明康德全新的泰兴原料药生产基地（五个基地中最大，占地68.4万平方米）投入运营，覆盖所有合成分子类型；一期预计2025年全面运营，反应釜总体积将超4,000立方米。
2025-04-01WuXi AppTec's Changzhou and Taixing API bases passed US FDA inspections with zero Form 483 observations in March 2025.药明康德常州及泰兴原料药基地于2025年3月以零缺陷通过美国FDA检查，未收到任何483表格。
2025-08-07WuXi AppTec's Changzhou and Taixing API bases passed FDA on-site inspections with zero observations in March 2025; the company expects total small-molecule reactor volume to exceed 4,000 kL by end of 2025.药明康德常州及泰兴原料药基地2025年3月以零缺陷通过FDA现场检查；预计2025年底小分子原料药反应釜总体积超过4000千升。
Capital returns: buybacks & dividends资本回报：回购与分红
63 · 2024-01-12 → 2026-08-03
▾
Recurring A-share and H-share buybacks, cancellations, and dividend distributions to enhance shareholder returns.持续的A股和H股回购、注销及分红派息以提升股东回报。
2024-01-12WuXi AppTec announced a restricted stock option exercise blackout period for the 2019 incentive plan's third exercise period, from January 18 to March 18, 2024.药明康德公告2019年限制性股票与股票期权激励计划首次授予股票期权第三个行权期限制行权期间为2024年1月18日至3月18日。
2024-01-18WuXi AppTec completed the repurchase and cancellation of 15.4675 million H-shares under the 2023 H-share reward trust plan, at a cost of approximately HKD 1.288 billion, reducing registered capital by RMB 15.4675 million.药明康德完成向受托人直接回购2023年H股奖励信托计划所涉1546.75万股H股并注销，回购价格约12.88亿港元，注册资本减少1546.75万元人民币。
2024-02-02WuXi AppTec announces a CNY 1 billion A-share buyback at up to CNY 100.9 per share, with all shares to be cancelled to reduce registered capital.药明康德公告拟以10亿元回购A股，价格上限100.9元/股，回购股份全部注销以减少注册资本。
2024-02-05WuXi AppTec completes the CNY 1 billion A-share buyback in one day, repurchasing 20.275 million shares (0.69% of total shares) at an average price of CNY 49.321 per share.药明康德一日内完成10亿元A股回购，回购2027.5万股（占总股本0.69%），均价49.321元/股。
2024-03-08WuXi AppTec announced a second A-share buyback of RMB 1 billion (up to RMB 83.33/share), shares to be cancelled to reduce registered capital, following a previous RMB 1 billion buyback completed on Feb 5, 2024.药明康德宣布第二轮10亿元A股回购（价格上限83.33元/股），回购股份将全部注销并减少注册资本，此前于2024年2月5日已完成首轮10亿元回购。
2024-03-11WuXi AppTec repurchased 937,079 A-shares for RMB 49.9955 million (first tranche of the second buyback plan) at prices between RMB 51.54 and 54.95 per share.药明康德以4999.55万元回购93.71万股A股（第二轮回购计划首次实施），回购价格区间为51.54元至54.95元/股。
2024-03-19WuXi AppTec announced it will cancel 20,275,407 A-shares (the first RMB 1 billion buyback completed on Feb 5, 2024) on Mar 20, 2024, reducing registered capital.药明康德公告将于2024年3月20日注销2024年2月5日完成回购的2027.54万股A股（首轮10亿元回购），减少注册资本。
2024-03-19WuXi AppTec announced it will cancel 20.275 million A-shares (first buyback) on Mar 20, 2024; combined with H-share buyback and second A-share buyback, total buyback and cancellation in 2024 exceeds RMB 3 billion.药明康德公告将于3月20日注销2027.5万股A股（首轮回购）；加上H股回购和第二轮A股回购，2024年回购注销总额超30亿元。
2024-04-01Completed first A-share buyback of RMB 1 billion on Feb 5, 2024; launched second A-share buyback of RMB 1 billion on Mar 8, 2024, with 6,519,226 shares repurchased as of Mar 31, 2024, total funds used RMB 331 million.2024年2月5日完成首轮10亿元A股回购；2024年3月8日启动第二轮10亿元A股回购，截至2024年3月31日已回购6,519,226股，使用资金3.31亿元。
2024-04-29Board approved 2023 dividend of RMB 2.88 billion on Mar 18, 2024; combined with ~RMB 3.2 billion in buyback and cancellation, total ~60% of 2023 net profit returned to shareholders.董事会于2024年3月18日审议通过2023年度分红28.8亿元；加上约32亿元回购注销，合计使用2023年约60%净利润回报股东。
2024-05-06WuXi AppTec announced that in April 2024 it repurchased 9.146 million A-shares for RMB 400 million; cumulative repurchases reached 15.6653 million shares for RMB 732 million as of April 30.药明康德公告2024年4月回购A股914.6万股，使用资金4亿元；截至4月30日累计回购1566.53万股，总金额约7.32亿元。
2024-05-23WuXi AppTec completed its second A-share repurchase on May 22, 2024, buying back 21.5938 million shares for RMB 1 billion (average price RMB 46.31/share); all shares will be cancelled on May 24.药明康德于2024年5月22日完成第二次A股回购，回购2159.38万股，使用资金10亿元（均价46.31元/股），全部股份将于5月24日注销。
2024-05-24WuXi AppTec announced the cancellation of 21,593,780 A-shares from its second repurchase on May 24, 2024, reducing registered capital.药明康德公告于2024年5月24日注销第二次回购的21,593,780股A股，减少注册资本。
2024-05-27WuXi AppTec announced its 2023 annual dividend plan: RMB 9.8336 per 10 shares (including tax), total cash dividend of approximately RMB 2.882 billion, representing 30% of net profit attributable to shareholders.药明康德公布2023年度利润分配方案：每10股派发现金红利9.8336元（含税），现金分红总额约28.82亿元，占归母净利润的30%。
2024-06-12Shareholders approved the 2023 final dividend of RMB 0.98974 per A-share (HKD 1.087 per H-share), with ex-dividend date on June 17, 2024 and payment on July 5, 2024.股东大会批准2023年末期股息每10股9.8974元人民币（每10股10.87港元），除净日为2024年6月17日，派息日为2024年7月5日。
2024-06-13WuXi AppTec completed two rounds of A-share buybacks totaling RMB 2 billion and an H-share buyback of HKD 1.288 billion in H1 2024, all cancelled; combined with the RMB 2.88 billion dividend, total shareholder returns reached nearly RMB 6 billion.药明康德2024年上半年完成两轮A股回购注销共20亿元及H股回购注销12.88亿港元，加上28.8亿元分红，累计向股东回馈近60亿元。
2024-07-12WuXi AppTec disclosed that since January 2024, it has completed H-share repurchases of approximately HK$1.288 billion and A-share repurchases of RMB 2 billion, all cancelled. The 2023 dividend of approximately RMB 2.88 billion, plus the repurchases, totals about 60% of 2023 net profit returned to shareholders.药明康德披露，自2024年1月以来已完成约12.88亿港币的H股回购和20亿元人民币的A股回购并全部注销。2023年度分红约28.8亿元，加上回购注销，共计使用2023年度约60%的净利润回报股东。
2024-08-01WUXI APPTEC completed H-share buybacks worth approximately 1.288 billion HKD and A-share buybacks worth 2 billion RMB since January 2024, all shares cancelled, totaling 57,336,687 shares or 1.97% of total share capital.药明康德自2024年1月以来完成约12.88亿港币H股回购和20亿元人民币A股回购，全部注销，累计注销57,336,687股，占总股本1.97%。
2024-09-10WuXi AppTec announced a third A-share buyback plan in 2024, with a total amount of RMB 1 billion, at a price not exceeding RMB 61.02 per share, for cancellation and capital reduction.药明康德宣布2024年第三次A股回购计划，总额10亿元，价格不超过61.02元/股，用于注销并减少注册资本。
2024-09-11WuXi AppTec executed the first tranche of the third A-share buyback, repurchasing 522,300 shares for approximately RMB 20.01 million.药明康德执行第三次A股回购首笔交易，回购52.23万股，耗资约2000.77万元。
2024-09-27WuXi AppTec completed the third A-share buyback, repurchasing 23.93 million shares (0.82% of total shares) for a total of RMB 1 billion, with an average price of RMB 41.78 per share.药明康德完成第三次A股回购，累计回购2393.46万股（占总股本0.82%），总额10亿元，均价41.78元/股。
2024-10-29WuXi AppTec cancels 23.93 million repurchased A-shares (0.82% of total shares) from its third buyback in 2024, reducing total shares from 2.912 billion to 2.888 billion.药明康德注销2024年第三次回购的2393万股A股（占总股本0.82%），总股本从29.12亿股减少至28.88亿股。
2025-03-17FY2024 final dividend: RMB 0.98169 per 10 shares, total ~RMB 2.835B; special dividend for 2025: RMB 0.35 per 10 shares, total ~RMB 1.011B; combined cash dividend and share buyback/cancellation of RMB 5.835B equals 61.75% of net profit.2024年度分红：每10股派9.8169元，合计约28.35亿元；2025年特别分红：每10股派3.5元，合计约10.11亿元；现金分红及回购注销合计58.35亿元，占净利润61.75%。
2025-03-17Announced a RMB 1B A-share buyback at ≤ RMB 92.05/share, to be cancelled to reduce registered capital; buyback period ≤12 months from shareholder approval.宣布以不超过92.05元/股回购10亿元A股，用于注销并减少注册资本；回购期限自股东大会批准起不超过12个月。
2025-03-17Board approved proposal to authorize the board to formulate a 2025 interim dividend plan, subject to shareholder approval; interim dividend capped at current-period net profit.董事会通过提请股东大会授权董事会制定2025年中期分红方案的议案；中期分红上限不超过当期归母净利润。
2025-04-08WuXi AppTec announced a second A-share buyback of RMB 1 billion at up to RMB 97.24 per share, with all shares to be cancelled.药明康德公告第二次A股回购方案，金额10亿元，价格上限97.24元/股，回购股份全部注销。
2025-04-09WuXi AppTec received a RMB 900 million loan commitment from Agricultural Bank of China (Shanghai branch) to fund its A-share buyback.药明康德取得中国农业银行上海市分行9亿元股票回购贷款承诺函。
2025-04-18WuXi AppTec executed its first A-share buyback under the new plan, repurchasing 379,300 shares for RMB 20.01 million.药明康德首次实施新回购计划，回购37.93万股，使用资金2000.87万元。
2025-04-29WuXi AppTec's 2024 AGM approved a special cash dividend of RMB 1 billion on top of the regular 30% payout, plus a 2025 first buyback plan of RMB 1 billion.药明康德2024年度股东大会通过额外10亿元特别现金分红及2025年第一次10亿元回购方案。
2025-05-06Adjusted 2024 annual dividend to total RMB 2.832 billion and 2025 special dividend to RMB 1.0098 billion, maintaining per-share amount unchanged after share buyback.调整2024年度分红总额为28.32亿元，2025年特别分红总额为10.098亿元，因回购导致总股本变动后维持每股分配金额不变。
2025-05-06As of April 30, 2025, repurchased ~2.86 million A-shares (0.0989% of total shares) for ~RMB 160 million, at prices between RMB 52.52 and 61.54 per share.截至2025年4月30日，累计回购A股约286万股（占总股本0.0989%），耗资约1.6亿元，回购价格区间52.52-61.54元/股。
2025-05-15Adjusted the upper price limit of the first 2025 buyback plan from RMB 92.05 to 90.72 per share, and the second from RMB 97.24 to 95.91 per share, due to dividend distribution.因分红调整，2025年第一次回购价格上限由92.05元/股下调至90.72元/股，第二次由97.24元/股下调至95.91元/股。
2025-05-15Implemented 2024 annual and 2025 special dividend: RMB 1.33169 per A-share (total ~RMB 3.327 billion), with record date May 20, 2025.实施2024年度及2025年特别分红：A股每股派现1.33169元（合计约33.27亿元），股权登记日2025年5月20日。
2025-05-22As of May 21, 2025, repurchased 3,337,716 A-shares (0.13% of total) for ~RMB 30 million under the second 2025 buyback plan; shares to be cancelled.截至2025年5月21日，2025年第二次回购计划累计回购A股333.77万股（占总股本0.13%），耗资约3000万元；回购股份拟注销。
2025-05-26Repurchased 480,000 A-shares on May 26, 2025, at prices between RMB 61.43 and 62.99, for RMB 30 million.2025年5月26日回购A股48万股，回购价格61.43-62.99元，支付金额3000万元。
2025-05-29Repurchased 470,000 A-shares on May 29, 2025, for RMB 30 million.2025年5月29日回购A股47万股，支付金额3000万元。
2025-05-31As of May 30, 2025, cumulative buyback under second 2025 plan reached ~4.681 million A-shares (0.02% of total) for ~RMB 299 million, at prices between RMB 52.75 and 64.56.截至2025年5月30日，2025年第二次回购计划累计回购约468.1万股A股（占总股本0.02%），耗资约2.99亿元，价格区间52.75-64.56元。
2025-06-23WuXi AppTec completed its second 2025 A-share buyback, repurchasing 15.7754 million shares (0.5462% of total) for RMB 1 billion at an average price of RMB 63.39/share; all shares were cancelled on June 24.药明康德完成2025年第二次A股回购，回购1577.54万股（占总股本0.5462%），金额10亿元，均价63.39元/股，全部于6月24日注销。
2025-06-26WuXi AppTec initiated its first 2025 A-share buyback plan (RMB 1 billion total), repurchasing 302,500 shares for RMB 20.01 million on the first day.药明康德启动2025年第一次A股回购计划（总额10亿元），首日回购30.25万股，金额2000.84万元。
2025-07-01Launched 2025 first A-share buyback program; by July 28, cumulatively bought back ~6.51M shares for ~RMB 497M (avg. price RMB 76.34).启动2025年首次A股回购计划；截至7月28日累计回购约651.44万股，耗资约4.97亿元（均价76.34元/股）。
2025-07-28Announced first-ever interim dividend of RMB 3.5 per 10 shares (approx. RMB 1.003B total), plus a special dividend of ~RMB 1B paid in May 2025.宣布首次中期分红，每10股派发现金红利3.5元（合计约10.03亿元）；2025年5月已派发特别分红约10亿元。
2025-07-29Adjusted A-share buyback price cap from RMB 90.72 to RMB 114.15 per share; total buyback amount remains RMB 1B.将A股回购价格上限从90.72元/股调整为114.15元/股，回购总额仍为10亿元。
2025-08-04WuXi AppTec disclosed that as of July 31, 2025, it had cumulatively repurchased 6.514 million A-shares (0.2268% of total shares) for RMB 497 million under its first 2025 buyback plan.药明康德披露截至2025年7月31日，已累计回购A股651.44万股（占总股本0.2268%），耗资4.97亿元。
2025-08-27WuXi AppTec completed its second A-share buyback of 2025, repurchasing 11.8608 million shares for RMB 1 billion (price range RMB 65.53-102.23), all to be cancelled; total 2025 buybacks reached RMB 2 billion, plus cash dividends totaling RMB 5.84 billion, representing over 60% of 2024 net profit.药明康德完成2025年第二轮A股回购，回购1186.08万股，耗资10亿元（价格区间65.53-102.23元），全部注销；2025年累计回购20亿元，加上现金分红合计58.4亿元，占2024年归母净利润60%以上。
2025-08-28WuXi AppTec announced its first-ever interim dividend: RMB 3.5 per 10 shares (approx. RMB 1 billion total), marking the third cash dividend in 2025.药明康德宣布首次中期分红：每10股派发现金红利3.5元（含税），总计约10亿元，为2025年第三次现金分红。
2025-09-05WuXi AppTec distributed approximately 4B RMB in cash dividends to shareholders in H1 2025, with an additional 1B RMB interim dividend pending; total buybacks and dividends for the year approached 7B RMB, exceeding 80% of net profit.药明康德2025年上半年向股东派发约40亿元现金分红，另有10亿元中期分红待实施；年内回购与分红总额近70亿元，占归母净利润比例超80%。
2025-09-08WuXi AppTec completed 5 share buybacks over the past 18 months totaling 5B RMB, with all shares cancelled to reduce registered capital; total cash returned to shareholders via dividends and buybacks reached nearly 12B RMB.药明康德过去18个月完成5次股份回购，累计金额50亿元，相关股份已全部注销以减少注册资本；通过分红与回购向股东返还总额近120亿元。
2025-11-10Cumulative cash dividends in 2025 reached RMB 4.88 billion, plus RMB 2 billion in share buybacks and cancellations, totaling RMB 6.88 billion returned to shareholders, exceeding 70% of 2024 net profit.2025年累计现金分红达48.8亿元，加上20亿元股份回购注销，合计向股东回报68.8亿元，占2024年归母净利润70%以上。
2025-11-18Implemented first-ever interim dividend in 2025, distributing RMB 1.03 billion; total 2025 dividends (annual, special, interim) reached RMB 4.88 billion.2025年首次实施中期分红，派发现金红利10.3亿元；全年通过年度分红、特别分红和中期分红累计派发现金红利48.8亿元。
2026-01-14At JPM conference, stated that since listing, cumulative cash dividends and share buybacks exceeded 20 billion yuan, accounting for >40% of cumulative net profit; 2025 shareholder returns totaled ~6.88 billion yuan (70%+ of 2024 net profit).在JPM大会上表示，上市以来累计现金分红与股份回购金额超200亿元，占累计净利润40%以上；2025年度股东回报合计约68.8亿元（占2024年净利润70%以上）。
2026-03-23Proposed 2026 interim dividend authorization; expected total FY2026 cash dividend >RMB 5.7B, second consecutive interim dividend.提请股东会授权2026年中期分红方案；预计2026年现金分红总额突破57亿元，连续第二年实施中期分红。
2026-03-23FY2025 total cash dividend (including interim & special) RMB 6.755B; share buyback & cancellation RMB 2.0B; total shareholder return RMB 8.755B, 45.72% of net profit.2025年全年现金分红（含中期及特别分红）67.55亿元；股份回购注销20亿元；股东回报合计87.55亿元，占净利润45.72%。
2026-04-20WuXi AppTec's 2025 annual report showed a total dividend plan of 5.745 billion yuan for the year, including a mid-term dividend of 1 billion yuan, marking the second consecutive year of implementing a mid-term dividend mechanism.药明康德2025年年报显示全年分红方案总额达57.45亿元，其中中期分红10亿元，连续第二年实施中期分红机制。
2026-05-07Shareholders meeting approved 2025 annual cash dividend and interim dividend plan; 2026 full-year cash dividend expected to hit record high.股东大会通过2025年年度现金分红及中期分红方案；2026年全年现金分红总额有望再创历史新高。
2026-05-22Announced 2025 annual dividend implementation: RMB 1.57927 per share (incl. tax), total ~RMB 4.712 billion, record date May 28, ex-dividend May 29.公布2025年年度权益分派实施：每股派发现金红利1.57927元（含税），合计约47.12亿元，股权登记日5月28日，除权除息日5月29日。
2026-05-27Repurchased 870,000 H-shares for HKD 111 million; total shares repurchased under authorization reached 1.55 million, representing 0.0518% of issued shares.回购87万股H股，总支付1.11亿港元；授权下累计回购155万股，占已发行股份的0.0518%。
2026-05-292025 fiscal year total cash dividends reached RMB 6.755 billion (including special dividend of ~RMB 1.01 billion and interim dividend of ~RMB 1.033 billion); cumulative dividends since listing ~RMB 18.77 billion, >37% of net profit.2025财年全年现金分红合计约67.55亿元（含特别分红约10.10亿元和中期分红约10.33亿元）；上市以来累计分红约187.70亿元，占归母净利润比重超37%。
2026-06-01WuXi AppTec implemented its 2025 cash dividend, setting a record high for payout amount, distributing approximately 82% of the sector's total cash dividends among top 20 CXO listed companies.药明康德实施2025年度现金分红，派现金额创历史新高，在国内TOP20 CXO上市公司中包揽板块82%的现金分红。
2026-06-09WuXi AppTec announced a plan to repurchase up to RMB 1 billion of its A-shares via centralized竞价 trading at a price not exceeding RMB 156.95 per share, for employee stock ownership plan.药明康德公告拟以自有资金10亿元，通过集中竞价交易方式回购A股股份，回购价格不超过156.95元/股，用于员工持股计划。
2026-06-11WuXi AppTec executed the first tranche of its A-share buyback, repurchasing 1,035,200 shares for approximately RMB 100 million at prices between RMB 95.59 and 97.54 per share.药明康德首次实施A股回购，回购股份103.52万股，使用资金约1亿元，回购价格区间95.59元/股至97.54元/股。
2026-06-17WuXi AppTec completed the H-share repurchase under the 2026 H-share Reward Trust Plan, using a total of HKD 2.5 billion to buy 20,148,900 H-shares (approx. 0.68% of total shares) as incentive stock sources.药明康德完成《2026年H股奖励信托计划》项下H股购回，累计使用资金25亿港元，购买2014.89万股H股（约占总股本0.68%），作为激励股份来源。
2026-06-25WuXi AppTec completed its A-share buyback plan, repurchasing a total of 9,701,231 shares (0.33% of total shares) for RMB 1 billion, at an average price of RMB 103.08 per share.药明康德完成A股回购计划，累计回购970.12万股（占总股本0.33%），使用资金10亿元，回购均价103.08元/股。
2026-08-03Declared interim dividend of RMB 5.10 per 10 shares (tax incl.), totaling RMB 1.506 billion, based on 2.954 billion shares.宣派中期股息每10股派发现金红利5.10元（含税），合计派发约15.06亿元。
US BIOSECURE Act & regulatory risk美国《生物安全法案》与监管风险
35 · 2024-01-26 → 2026-08-07
▾
Persistent US legislative and regulatory pressure, clarifications, and legal challenges.持续的美国立法和监管压力、澄清及法律挑战。
2024-01-26WuXi AppTec was named in a draft U.S. Biosecure Act submitted to the House on January 25, 2024, and a similar Senate draft; the company issued a clarification stating the content is inaccurate and its business poses no national security risk.药明康德被提及于2024年1月25日提交美国众议院的《生物安全法案》草案及类似参议院草案中；公司发布澄清公告，称相关内容不准确，业务发展不会对任何国家安全构成风险。
2024-01-27WuXi AppTec held a conference call responding to the Biosecure Act draft, denying sponsorship of military-civilian fusion projects, receiving direct investment from related funds, and clarifying that its life chemistry award criteria are based solely on scientific merit.药明康德召开电话会回应《生物安全法案》草案，否认赞助军民融合项目、接受相关基金直接投资，并澄清生命化学研究奖评选标准仅基于科研能力。
2024-01-29WuXi AppTec issued a stock trading异常波动公告 after its A-share price fell over 20% in three consecutive trading days (Jan 25, 26, 29), reiterating that the Biosecure Act draft content is inaccurate and business operations are normal.药明康德发布股票交易异常波动公告，A股于1月25日、26日、29日连续三个交易日收盘价格跌幅偏离值累计超20%，重申《生物安全法案》草案内容不准确，生产经营正常。
2024-02-01WuXi AppTec clarifies that the Biosecure Act draft bill has not taken effect and its content is still under review.药明康德澄清《生物安全法案》草案尚未生效，内容仍待审议。
2024-02-04WuXi AppTec issues further clarification stating it has no human genomics business, does not collect human genomic data, and poses no national security risk to any country.药明康德进一步澄清，公司没有人类基因组学业务，不收集人类基因组数据，不对任何国家构成国家安全风险。
2024-02-05WuXi AppTec management issues an open letter to clients, reiterating that the company poses no national security risk and is actively communicating with relevant parties.药明康德管理团队发布致客户公开信，重申不对任何国家构成国家安全风险，并正积极与相关方沟通。
2024-02-05US Senate version of the Biosecure Act (S.3558) is postponed, failing to pass committee review as previously expected.美参院版《生物安全法案》（S.3558）推迟审议，未能按预期通过委员会审议。
2024-02-13US lawmakers send a letter to the US Departments of Commerce, Treasury, and Defense on February 12 regarding WuXi AppTec; the company strongly opposes misleading allegations.美国议员于2月12日致函美国商务部、财政部和国防部，内容涉及药明康德；公司强烈反对误导性指称。
2024-02-18WuXi AppTec issues further clarification, emphasizing it has never posed a national security risk to the US and clarifying its English name 'WuXi AppTec Co., Ltd.'药明康德再次澄清，强调从未对美国构成国家安全风险，并澄清公司英文名称为'WuXi AppTec Co., Ltd.'。
2024-03-07US Senate Homeland Security Committee voted 11-1 to advance revised BIOSECURE Act (S.3558), which pre-designates WuXi AppTec as a 'company of concern', restricting US federal contracts. WuXi AppTec strongly opposes and reiterates it has no human genomics business.美国参议院国土安全委员会以11-1投票通过修订后的《生物安全法案》(S.3558)，将药明康德预先定义为“予以关注的生物技术公司”，限制美国联邦合同。药明康德强烈反对，并重申其没有人类基因组学业务。
2024-03-14Biotechnology Innovation Organization (BIO) announced it would expel WuXi AppTec as a member and support the BIOSECURE Act; later on Mar 15, BIO updated the statement to say WuXi AppTec voluntarily terminated its membership.美国生物技术创新组织(BIO)宣布将剔除药明康德的会员资格并支持《生物安全法案》；3月15日，BIO更新声明称药明康德主动终止了其会员资格。
2024-03-19WuXi AppTec stated on the FY2023 earnings call that it proactively wrote to terminate BIO membership on Mar 12 to allow BIO to focus on industry advocacy; business and client relationships remain solid with new orders in Jan-Feb 2024 proceeding normally.药明康德在2023年业绩电话会上表示，于3月12日主动致信退出BIO，以便BIO专注于行业倡导；业务和客户关系依然牢固，2024年1-2月新签订单正常进行。
2024-03-19WuXi AppTec stated on the earnings call that the BIOSECURE Act's 'grandfather clause' would only restrict contracts involving US government funding if signed after the act's effective date; existing long-term contracts signed before enactment would not be affected.药明康德在业绩电话会上表示，《生物安全法案》的“祖父条款”仅限制法案生效后签订的涉及美国政府资助的合同；生效前已签订的长期合同不受影响。
2024-04-30At Q1 earnings call, stated no mass customer order cancellations due to US BIOSECURE Act; only a few early-stage R&D clients canceled some services; over 300 new clients added in Q1, ~40% from Europe and US.一季度业绩会上表示，未出现因美国《生物安全法案》导致客户大量取消订单的情况；仅极个别早期研发客户取消部分服务；一季度新增客户超300家，约40%来自欧美。
2024-05-10WuXi AppTec responded to investor queries on the US BIOSECURE Act, stating the draft has not taken effect, the legislative process requires multiple steps, and the content is subject to change; the company will continue to assess potential impacts.药明康德回应投资者关于美国《生物安全法案》的提问，表示草案尚未生效，立法程序需多个步骤，内容可能变更；公司将持续评估潜在影响。
2024-05-16WuXi AppTec announced that the US House Committee voted 40-1 to report H.R.8333, a revised BIOSECURE Act draft; it removed previous allegations against WuXi AppTec and added a grandfather clause for existing contracts, but still lists the company as a 'covered biotechnology company'; the company strongly opposes this.药明康德公告美国众议院委员会以40-1投票通过H.R.8333修订版《生物安全法案》草案，移除此前针对药明康德的指称并增加现有合同豁免条款，但仍将其列为“予以关注的生物技术公司”，公司强烈反对。
2024-05-16The revised BIOSECURE Act H.R.8333 requires US companies to end cooperation with WuXi AppTec and other Chinese biotech firms by January 1, 2032, providing an 8-year transition period.修订版《生物安全法案》H.R.8333要求美国公司在2032年1月1日前结束与药明康德等中国生物技术公司的合作，提供8年缓冲期。
2024-05-22Moody's affirmed WuXi AppTec's Baa2 issuer rating but changed the outlook from stable to negative, citing uncertainty from the proposed US BIOSECURE Act.穆迪确认药明康德Baa2发行人评级，但将展望从稳定调整为负面，理由是美国拟议《生物安全法案》带来的不确定性。
2024-06-03Fitch placed WuXi AppTec's 'BBB' long-term issuer rating and senior unsecured rating on negative watch, citing potential regulatory risks from the U.S. BIOSECURE Act draft.惠誉将药明康德'BBB'长期发行人评级和高级无抵押评级列入负面观察名单，理由是美国生物安全法草案带来潜在监管风险。
2024-06-12WuXi AppTec management stated at the 2023 AGM that the amendment to add the BIOSECURE Act (H.R.8333) to the NDAA failed to pass the House Rules Committee, so the bill will not enter the House NDAA legislative agenda for now; the subsequent legislative path remains unclear.药明康德管理层在2023年股东大会上表示，将《生物安全法案》(H.R.8333)加入NDAA的修正案未获众议院规则委员会批准，因此该法案目前不会进入众议院NDAA立法议程，后续立法路径尚不明确。
2024-06-18WuXi Biologics (related entity) paused construction of its Worcester, Massachusetts facility, citing normal internal design adjustments; market speculation linked it to the BIOSECURE Act.药明生物暂停美国伍斯特基地建设，称是内部正常设计调整；市场猜测与《生物安全法案》有关。
2024-06-21WuXi AppTec confirmed it has never received any sanctions from U.S. government agencies and operations remain stable.药明康德确认从未受到美国政府机构任何制裁，运营稳定。
2024-07-29WuXi AppTec disclosed that the Biosecure Act (H.R.8333) amendment to the NDAA was proposed in the Senate on July 10, 2024, and is under review by the Senate Armed Services Committee. The legislative path remains uncertain.药明康德披露，基于H.R.8333草案的《生物安全法案》修正案于2024年7月10日在参议院被提出，目前正由参议院军事委员会审议。立法路径仍具有不确定性。
2024-09-10The U.S. House of Representatives passed the Biosecure Act (H.R.8333) draft, designating WuXi AppTec as a 'company of concern'; the bill includes a grandfather clause allowing existing U.S. government-funded contracts until 2032.美国众议院通过《生物安全法》草案（H.R.8333），将药明康德指定为“予以关注的生物技术公司”；法案包含祖父条款，允许现有美国政府资助合同履行至2032年。
2024-09-10WuXi AppTec reiterated that it has no human genomics business and does not collect human genomic data in any region.药明康德重申其没有人类基因组学业务，且在任何地区均不收集人类基因组数据。
2024-09-25A revised U.S. Biosecure Act amendment removed WuXi Biologics from the list, but WuXi AppTec, BGI, MGI, and Complete Genomics remain designated; the bill was renamed the 'Prohibiting Foreign Access to American Genetic Information Act'.美国《生物安全法》修正案将药明生物从名单中移除，但药明康德、华大基因、华大智造及Complete Genomics仍在列；法案更名为《禁止外国获取美国基因信息法》。
2024-11-18At Q3 earnings call, Vice Chairman Hu Zhengguo stated the Biosecure Act's passage remains uncertain in the current Congress; US election has no direct impact on the legislative process.在三季度业绩说明会上，副董事长胡正国表示《生物安全法案》在本届国会任期内能否通过仍存在不确定性；美国大选对立法流程无直接影响。
2024-12-09The Biosecure Act (S.3558/H.R.8333) was not included in the final negotiated text of the FY2025 National Defense Authorization Act (NDAA), significantly reducing the likelihood of the bill becoming law this year.生物安全法案（S.3558/H.R.8333）未被纳入2025财年国防授权法案（NDAA）最终协商文本，年内成为法律的可能性大幅降低。
2025-02-24WuXi AppTec H-shares fell over 8% after reports that President Trump instructed CFIUS to restrict Chinese investments in US technology, energy, biotech, and other strategic sectors.药明康德港股跌超8%，因报道称特朗普指示美国外国投资委员会限制中国在美技术、能源、生物技术等战略领域的投资。
2025-03-18Management commented on US tariff policy: impact on business requires further observation; on BIOSECURE Act: no related proposal heard in new US Congress, will monitor legislative developments.管理层回应美国关税政策：对业务影响需进一步观察；回应《生物安全法案》：新一届国会尚未听到相关提案，将持续关注立法动态。
2025-04-10WuXi AppTec refuted allegations in a US National Security Commission report as 'far-fetched and baseless', stating it has never transferred US client data or IP to third parties without authorization.药明康德回应美国新兴生物技术国家安全委员会报告，称其指控牵强附会且毫无根据，从未未经授权转移美国客户数据或知识产权。
2025-06-11WuXi AppTec responded to the US National Security Commission on Emerging Biotechnology report, stating it has never transferred US client data or IP without authorization and has communicated with US agencies to clarify facts.药明康德回应美国新兴生物技术国家安全委员会报告，称从未未经授权转移美国客户数据或知识产权，并已与美国政府机构沟通澄清。
2026-06-09U.S. Department of Defense erroneously added WuXi AppTec to the updated 'Chinese Military Company' list under Section 1260H; WuXi AppTec stated the designation is wrong and will immediately challenge it.美国国防部错误地将药明康德列入根据1260H条款认定的'中国军工企业'正式更新版名单；药明康德声明该认定错误，将立即采取措施挑战纠正。
2026-06-11WuXi AppTec filed a lawsuit in the U.S. District Court for the District of Columbia against the Department of Defense, seeking to invalidate the CMC designation and remove the company from the 1260H list.药明康德在美国哥伦比亚特区联邦地区法院对美国国防部提起诉讼，请求宣告CMC认定无效、撤销决定并将公司从1260H名单中移除。
2026-08-07US District Court for DC granted WuXi AppTec's preliminary injunction, barring DoD from enforcing its 1260H 'Chinese military company' designation during litigation; court found DoD's designation arbitrary and caused irreparable harm.美国哥伦比亚特区联邦地区法院批准药明康德初步禁令，禁止国防部在诉讼期间执行1260H‘中国军工企业’认定；法院认为国防部认定武断且造成不可弥补损害。
Institutional shareholding changes机构持股变动
11 · 2024-02-21 → 2026-07-27
▾
Fluctuations in stakes held by major institutional investors like BlackRock, JPMorgan, and UBS.贝莱德、摩根大通和瑞银等主要机构投资者持股比例的波动。
2024-02-21The Capital Group Companies, Inc. increases its stake in WuXi AppTec H-shares by 975,500 shares on February 15 at an average price of HKD 38.433 per share.美国资本集团于2月15日增持药明康德H股97.55万股，均价38.433港元/股。
2024-03-13JPMorgan Chase increased its H-share holding in WuXi AppTec by 1.654 million shares at an average price of ~HKD 46.96 per share, raising its stake from 9.88% to 10.31%.摩根大通以均价约46.96港元/股增持药明康德H股165.4万股，持股比例由9.88%升至10.31%。
2024-07-23BlackRock increased its stake in WuXi AppTec H-shares to 6.41% on July 18, 2024, from 5.46%, adding 3.6896 million shares.贝莱德于2024年7月18日增持药明康德H股368.96万股，持仓比例由5.46%增至6.41%。
2024-07-24BlackRock reduced its stake in WuXi AppTec H-shares to 5.48% on July 19, 2024, from 6.43%.贝莱德于2024年7月19日减持药明康德H股，持仓比例由6.43%下降至5.48%。
2024-07-24JPMorgan increased its short position in WuXi AppTec H-shares to 2.10% on July 24, 2024, from 1.49%.摩根大通于2024年7月24日将药明康德H股的空头持仓从1.49%上调至2.10%。
2024-08-01BlackRock reduced its long position in WUXI APPTEC H-shares from 6.17% to 5.47% on July 29, 2024.贝莱德于2024年7月29日将药明康德H股多头持仓从6.17%减少至5.47%。
2025-02-10UBS increased its long position in WuXi AppTec H-shares from 4.50% to 5.57% on February 4, 2025, as disclosed in HKEX filings.港交所文件显示，瑞银在药明康德H股长期持仓比例于2月4日由4.50%上升至5.57%。
2026-06-24UBS increased its long position in WuXi AppTec H-shares from 7.7% to 8.03% on June 17, 2026.瑞银集团于2026年6月17日将药明康德H股的多头持仓比例从7.7%增至8.03%。
2026-07-23JPMorgan increased its long position in WUXI APPTEC H-shares from 10.98% to 11.39% on July 20, 2026, at an average price of HKD 156.2519.摩根大通于2026年7月20日将药明康德H股多头持仓从10.98%增至11.39%，平均股价156.2519港元。
2026-07-24FMR LLC reduced its stake in WUXI APPTEC H-shares from 9.17% to 8.83% on July 21, 2026, at an average selling price of HKD 153.6863.FMR LLC于2026年7月21日将药明康德H股持股比例从9.17%降至8.83%，平均卖出价153.6863港元。
2026-07-27BlackRock increased its long position in WUXI APPTEC H-shares from 5.66% to 6.06% on July 21, 2026.贝莱德于2026年7月21日将药明康德H股多头持仓从5.66%升至6.06%。
WuXi ATU (cell & gene therapy) divestiture药明生基（细胞与基因治疗）业务剥离
9 · 2024-02-23 → 2025-03-17
▾
Evaluation and eventual sale of the WuXi ATU cell and gene therapy business to Altaris.评估并最终将药明生基细胞与基因治疗业务出售给Altaris。
2024-02-23WuXi AppTec subsidiary WuXi ATU announces FDA approval of its Philadelphia facility for analytical testing and production of T-cell therapy AMTAGVI, the first FDA-approved TIL therapy for solid tumors.药明康德子公司药明生基宣布，美国FDA批准其费城基地进行T细胞免疫疗法AMTAGVI的分析测试和生产，AMTAGVI是全球首款获批的实体瘤TIL疗法。
2024-03-18WuXi AppTec signed a commercial CAR-T product LVV production order in June 2023; process validation underway, production expected to start in H1 2024.药明康德于2023年6月签订一项商业化CAR-T产品的LVV生产订单，正在进行工艺验证，预计2024年上半年开始生产。
2024-07-29WuXi AppTec is preparing for a BLA submission for the lentiviral vector (LVV) production of a commercial CAR-T product. Process performance qualification (PPQ) is complete, and post-PPQ production has started. FDA submission is expected in H2 2024.药明康德正在为一项商业化CAR-T产品的慢病毒载体（LVV）生产做BLA申报准备。已完成工艺验证（PPQ），开始PPQ后的生产，预计2024年下半年向FDA申报。
2024-08-01WUXI APPTEC's high-end therapy CTDMO business revenue in H1 2024 fell 19.43% YoY, due to early-stage commercial projects, delays, cancellations, and impact from proposed US BIOSECURE Act.药明康德高端治疗CTDMO业务2024年上半年收入同比下降19.43%，原因包括商业化项目处于早期、延迟、客户取消以及美国拟议《生物安全法案》的影响。
2024-10-04WuXi AppTec confirms it is evaluating options for its WuXi Advanced Therapies (ATU) cell and gene therapy business, including a potential sale, but has not formed any resolution or signed binding agreements as of Oct 8.药明康德确认正在评估其WuXi Advanced Therapies（高端治疗CTDMO业务）的运营选项，包括潜在出售，但截至10月8日尚未形成任何决议或签署有约束力的协议。
2024-12-24WuXi AppTec signed a Share Purchase Agreement to sell 100% equity of WuXi Advanced Therapies Inc. (US) and Oxford Genetics Limited (UK), the operating entities of its WuXi ATU (cell & gene therapy CTDMO) business, to US healthcare-focused equity fund Altaris LLC for cash. The transaction is expected to close in H1 2025.药明康德签署股权购买协议，将其WuXi ATU业务（细胞及基因疗法CTDMO）的美国运营主体WuXi Advanced Therapies Inc.和英国运营主体Oxford Genetics Limited的全部股权以现金对价方式转让给美国医疗保健股权投资基金Altaris LLC。交易预计在2025年上半年完成。
2024-12-24The sold WuXi ATU entities (Advanced Therapies and Oxford Genetics) had combined revenue of approximately RMB 9.8 billion (unaudited) from Jan-Nov 2024, representing 2.4% of WuXi AppTec's latest audited annual revenue.被出售的WuXi ATU实体（Advanced Therapies和Oxford Genetics）在2024年1至11月合计营业收入约人民币9.8亿元（未经审计），占药明康德最近一个会计年度经审计营业收入的2.4%。
2025-01-02Sold all equity of WuXi ATU US (Advanced Therapies) and UK (Oxford Genetics) operations to US healthcare fund Altaris for cash; deal expected to close H1 2025.将WuXi ATU美国（Advanced Therapies）和英国（Oxford Genetics）业务全部股权以现金方式出售给美国医疗基金Altaris；交易预计2025年上半年完成。
2025-03-17Completed sale of WuXi ATU US and UK operations to Altaris LLC, and sale of US medical device testing business to NAMSA; both transactions closed in 2024, contributing combined revenue of RMB 1.32B.完成向Altaris LLC出售WuXi ATU美国和英国业务，以及向NAMSA出售美国医疗器械测试业务；两项交易均在2024年完成交割，合计贡献收入13.2亿元。
Controlling shareholder stake reductions控股股东减持
9 · 2024-02-23 → 2026-01-06
▾
Planned and executed reductions of A-share holdings by controlling shareholders and concert parties.控股股东及其一致行动人计划并执行的A股减持。
2024-02-23Shareholder Summer Bloom Investments (I) Pte. Ltd. completes its减持 plan, selling 0.5389% of total shares via centralized竞价 from November 2 to November 28, 2023.股东Summer Bloom Investments (I) Pte. Ltd.完成减持计划，于2023年11月2日至28日通过集中竞价减持总股本的0.5389%。
2025-10-09Shareholders Ge Li (Li Ge) and former concert parties Eastern Star, Fertile Harvest, and LC terminated the concert party agreement; voting rights of concert parties decreased from 20.16% to 18.46%.股东李革(GeLi)与原一致行动人EasternStar、FertileHarvest和LC解除一致行动关系协议；一致行动人表决权比例从20.16%下降至18.46%。
2025-10-29Shareholders controlled by actual controller plan to reduce A-share holdings by up to 2% of total share capital (max 59,675,143 shares) via block trade and/or centralized竞价 within 3 months starting Nov 20, 2025, due to own capital needs.实际控制人控制的股东计划自2025年11月20日起3个月内通过集中竞价和/或大宗交易减持不超过总股本2%的A股（最多59,675,143股），原因为自身资金需求。
2025-11-12Controlling shareholders announced a plan to reduce holdings by up to 2% of total A-share capital; management stated the reduction is based on shareholders' own needs.实际控制人宣布减持不超过总股本2%的A股股份；管理层表示减持是股东基于自身需求所做的决定。
2025-11-26From Nov 20 to Nov 25, 2025, controlling shareholders reduced holdings by 11,827,898 A-shares (0.40% of total share capital) via centralized竞价, reducing combined stake from 18.46% to 17.95%.2025年11月20日至25日，实际控制人控制的股东通过集中竞价方式合计减持公司股份11,827,898股（占总股本0.40%），合计持股比例从18.46%降至17.95%。
2025-12-0117 shareholders plan to reduce holdings by up to 2% of total A-share capital, sourced from IPO pre-investment shares, with most institutions in the 7-10 year exit window.17名股东计划减持不超过总股本2%的A股股份，股份来源于IPO前投资，多数机构处于7-10年退出窗口期。
2025-12-18Controlling shareholders' concert parties reduced holdings by 29.5088 million shares (0.989% of total capital) from Nov 26 to Dec 17, 2025 via block and centralized trading; total shareholding dropped from 17.95% to 16.97%.控股股东一致行动人于2025年11月26日至12月17日通过集中竞价和大宗交易合计减持2950.88万股（占总股本0.989%）；持股比例从17.95%降至16.97%。
2025-12-22From Nov 20 to Dec 17, 2025, controlling shareholders' concert parties cumulatively reduced ~41.34 million shares, cashing out approximately 3.8 billion yuan at an average price of 91.84 yuan per share; total historical cash-out by actual controller and affiliates reached 10.281 billion yuan.2025年11月20日至12月17日，控股股东一致行动人累计减持约4134万股，按均价91.84元/股计算套现约38亿元；实际控制人及其关联方历史累计套现达102.81亿元。
2026-01-06Controlling shareholders completed a 2% stake reduction, selling 59.68 million shares via block and open-market trades at 84.66-95.08 yuan/share, with total proceeds of about 5.34 billion yuan.实际控制人控制的股东完成2%股份减持，通过大宗交易和集中竞价方式累计减持5968万股，减持价格区间84.66-95.08元/股，合计套现约53.43亿元。
Share unlocks & placements股份解禁与配售
6 · 2024-03-07 → 2025-08-07
▾
Restricted share unlocks, H-share top-up placements, and related capital raising activities.限制性股票解禁、H股增发配售及相关融资活动。
2024-03-078.36 million restricted shares (equity incentive) became tradable on Mar 7, 2024, representing 0.0% of total share capital.2024年3月7日，836万股股权激励限售股份解禁上市，占总股本0.0%。
2024-03-2210.14 million restricted shares (equity incentive) became tradable on Mar 22, 2024, representing 0.0% of total share capital; after this unlock, the company has no remaining restricted shares.2024年3月22日，10.14万股股权激励限售股份解禁上市，占总股本0.0%；本次解禁后公司无限售股份。
2025-07-31Launched H-share top-up placement of 73.8M new H-shares at HK$104.27 each, raising net proceeds of ~HK$7.65B; ~90% of proceeds for global expansion and capacity building.启动H股配售，发行7380万股新H股，配售价104.27港元/股，募资净额约76.5亿港元；约90%用于全球布局和产能建设。
2025-08-01WuXi AppTec completed a HKD 7.7 billion H-share top-up placement of 73.8 million shares at HKD 104.27 per share, with net proceeds of approximately HKD 7.647 billion, of which about 90% will be used for global expansion and capacity construction.药明康德完成77亿港元H股配售，发行7380万股，每股104.27港元，净募资约76.47亿港元，其中约90%用于全球布局和产能建设。
2025-08-01WuXi AppTec's H-share placement was multiple times oversubscribed by investors, according to foreign media reports.据外媒消息，药明康德H股配售获得投资者多倍超额认购。
2025-08-07WuXi AppTec completed the H-share placement of 73.8 million shares, raising net proceeds of approximately HKD 7.647 billion, with about 90% allocated to global expansion and capacity construction.药明康德完成7380万股H股配售，净募资约76.47亿港元，约90%用于全球布局和产能建设。
Small-molecule CDMO (DM) pipeline小分子CDMO（DM）管线
15 · 2024-03-18 → 2026-08-03
▾
Continuous expansion of the small-molecule development and manufacturing pipeline and commercial projects.小分子开发和生产管线及商业化项目的持续扩张。
2024-03-18WuXi AppTec's DM (process R&D and manufacturing) pipeline added 1,255 new molecules in 2023, reaching a total of 3,201 molecules; ex-COVID DM revenue grew 55.1% YoY.药明康德2023年DM（工艺研发和生产）分子管线新增1255个分子，总数达3201个；剔除新冠项目后DM收入同比增长55.1%。
2024-04-29Chemistry business (WuXi Chemistry) DM molecule pipeline totaled 3,286 at end of Q1 2024; 11 new commercial and Phase III projects added in Q1; DM service revenue RMB 4.00 billion, ex-COVID up 1.2% YoY.化学业务（WuXi Chemistry）DM分子管线截至2024年一季度末总计3,286个；一季度新增11个商业化和临床III期项目；DM服务收入40.0亿元，剔除新冠同比增长1.2%。
2024-07-29WuXi AppTec's small molecule DM pipeline reached 3,319 molecules as of June 30, 2024, a record high. 644 new molecules were added in H1 2024, including 14 new commercial and Phase III projects.截至2024年6月30日，药明康德小分子DM管线总数达到3319个，创历史新高。2024年上半年新增分子644个，其中新增商业化和临床III期项目14个。
2024-08-01WUXI APPTEC's small molecule D&M pipeline expanded: 644 new molecules added in H1 2024, total pipeline reached 3,319 molecules including 67 commercial projects.药明康德小分子D&M管线扩张：2024年上半年新增644个分子，管线总数达3319个分子，包括67个商业化项目。
2024-10-28WuXi AppTec's small-molecule CDMO pipeline expands: 915 new molecules added in 9M 2024, total 3,356 molecules as of Sep 2024, +11.35% YoY.药明康德小分子CDMO管线扩张：2024年前三季度新增915个分子，截至9月底总数达3356个，同比增长11.35%。
2025-03-17FY2024 chemical (WuXi Chemistry) revenue RMB 29.05B, ex-specific commercial projects +11.2% YoY; small-molecule DM pipeline added 1,187 new molecules in 2024; total DM pipeline 3,377, with 25 commercial/Phase III projects added.2024年化学业务收入290.5亿元，剔除特定商业化项目同比+11.2%；小分子DM管线新增1187个分子；DM管线总计3377个，新增25个商业化和临床III期项目。
2025-07-28Small molecule CDMO pipeline reached 3,409 projects; DM pipeline added 412 new molecules (158 from R-to-D); added 8 commercial/Phase III projects in H1 2025.小分子CDMO管线项目达3409个；DM管线新增412个分子（其中158个由R端转化）；2025年上半年新增8个商业化及III期项目。
2025-11-21Small-molecule pipeline: R-end delivered over 430,000 compounds in past 12 months; D-end added 621 new molecules in first three quarters, total 3,430 molecules including 80 commercial and 87 Phase III projects.小分子管线：过去12个月R端交付超过43万个化合物；前三季度D端新增621个分子，总数达3430个，包括80个商业化项目和87个临床III期项目。
2026-01-14At JPM conference, stated that as of Q3 2025, small-molecule CDMO pipeline totaled 3,430 molecules (16% of global clinical-stage small-molecule drugs), with 80 commercial-stage molecules and 167 phase III/commercial projects.在JPM大会上表示，截至2025年三季度，小分子CDMO管线总数达3430个（占全球临床阶段小分子新药16%），其中商业化分子80个，三期及商业化项目167个。
2026-03-23FY2025 small-molecule pipeline supported 8 of 30 FDA-approved small-molecule drugs; 4 of top 10 global chemical drugs by 2024 sales served.2025年公司支持了美国FDA批准的30款小分子药物中的8款；2024年全球销售额前10的化学合成药物中，公司服务生产4款。
2026-04-27WuXi AppTec's small-molecule CDMO (DM) business revenue in Q1 2026 was 6.93 billion yuan, up 80.1% YoY, a single-quarter record surpassing the peak during the COVID-19 commercialization period.药明康德2026年第一季度小分子CDMO（DM）业务收入69.3亿元，同比增长80.1%，单季规模创历史新高，超越了新冠商业化项目高峰期的收入峰值。
2026-04-27WuXi AppTec's small-molecule DM pipeline added 328 new molecules in Q1 2026, reaching a total of 3,550. Commercial and Phase III projects increased by 9.药明康德2026年第一季度小分子DM管线新增分子328个，总规模达3550个。商业化和临床III期项目新增9个。
2026-08-03H1 2026 chemistry business revenue rose 53.3% YoY to RMB 24.986 billion; small-molecule DM revenue grew 72.7% to RMB 14.99 billion; DM pipeline reached 3,731 molecules.2026年上半年化学业务收入249.86亿元，同比增长53.3%；小分子DM业务收入149.9亿元，同比增长72.7%；DM管线总数达3731个。
2026-08-03H1 2026 small-molecule DM business added 699 new pipeline molecules; commercial and Phase III projects increased by 15.2026年上半年小分子DM业务新增管线分子699个；商业化及III期项目新增15个。
2026-08-03H1 2026 small-molecule DM business added 699 new pipeline molecules; commercial and Phase III projects increased by 15.2026年上半年小分子DM业务新增管线分子699个；商业化及III期项目新增15个。
Corporate governance & articles amendments公司治理与章程修订
10 · 2024-03-18 → 2026-03-24
▾
Updates to articles of association, board procedures, and governance structures.对公司章程、董事会程序和治理结构的更新。
2024-03-18WuXi AppTec's board approved amendments to the company's articles of association to comply with new CSRC and HKEX rules on overseas listing, independent directors, cash dividends, and share buybacks.药明康德董事会批准修改公司章程，以符合中国证监会和港交所关于境外上市、独立董事、现金分红和股份回购的新规。
2024-12-31WuXi AppTec announced it will hold its first extraordinary general meeting of 2025 on January 22, 2025, to consider the election of an independent director for the third board of directors.药明康德公告将于2025年1月22日召开2025年第一次临时股东大会，审议补选公司第三届董事会独立董事的议案。
2025-01-222025 first extraordinary general meeting approved the by-election of an independent director for the third board.2025年第一次临时股东大会审议通过了补选第三届董事会独立董事的议案。
2025-09-02WuXi AppTec proposed to cancel its supervisory board, change registered capital from 2,887,992,582 to 2,951,506,736 RMB, and amend the company's articles of association, to be voted at the 2nd extraordinary general meeting on 2025-09-23.药明康德提议取消监事会，将注册资本从2,887,992,582元变更为2,951,506,736元，并修改公司章程，提交2025年9月23日第二次临时股东大会审议。
2025-09-02WuXi AppTec's board submitted a renewed share disposal authorization to the general meeting, after previously disposing listed stocks with proceeds equal to 3.99% of net assets, citing market volatility.药明康德董事会将处置股份授权提请股东大会审议，此前已处置部分上市公司股票，成交金额占净资产的3.99%，因市场波动无法预估后续影响。
2025-09-02WuXi AppTec's board approved revised rules for the Nomination Committee, requiring a majority of independent directors and at least one director of a different gender.药明康德董事会审议通过修订后的《董事会提名委员会议事规则》，要求独立董事过半数并至少包含一名不同性别董事。
2025-09-02WuXi AppTec's board approved revised Board Rules of Procedure, enhancing governance and decision-making transparency, effective immediately.药明康德董事会审议通过修订后的《董事会议事规则》，强化治理与决策透明度，即日生效。
2025-09-02WuXi AppTec's board approved a revised Information Disclosure Management System, strengthening insider information control and disclosure procedures.药明康德董事会审议通过修订后的《信息披露管理制度》，强化内幕信息管控和披露程序。
2026-03-23Board approved change of registered capital to RMB 2.983757155B due to H-share convertible bond conversion, and amendment of articles of association.因H股可转债转股，注册资本变更为29.83757155亿元，并相应修改公司章程。
2026-03-24Board nominated five independent director candidates: Christine Shaohua Lu-Wong, Wei Yu, Xin Zhang, Zhan Zhiling, Leng Xuesong.董事会提名五位独立董事候选人：卢韶华、俞卫、张新、詹智玲、冷雪松。
Testing & biology segment performance测试与生物学板块业绩
3 · 2024-04-29 → 2026-08-03
▾
Performance of the testing and biology business segments, including drug safety evaluation.测试和生物学业务板块的表现，包括药物安全评价。
2024-04-29Q1 2024 testing business revenue up 2.60% YoY; biology business down 2.81%; ATU CTDMO business down 13.63%; domestic new drug R&D service down 51.75%; other down 29%.2024年一季度测试业务收入同比增长2.60%；生物学业务同比下降2.81%；高端治疗CTDMO业务同比下降13.63%；国内新药研发服务部同比下降51.75%；其他同比下降29%。
2026-08-03H1 2026 testing business revenue rose 31.5% to RMB 2.481 billion; drug safety evaluation revenue grew 42.8%.2026年上半年测试业务收入24.81亿元，同比增长31.5%；药物安全性评价业务收入同比增长42.8%。
2026-08-03H1 2026 biology business revenue reached RMB 1.392 billion, up double digits; DEL platform served over 1,500 clients with 90 billion compounds.2026年上半年生物学业务收入13.92亿元，实现双位数增长；DEL平台服务客户超1500个，化合物分子数量超900亿个。
Revenue breakdown by geography按地区收入分解
6 · 2024-04-29 → 2026-03-23
▾
Quarterly and annual revenue figures segmented by US, Europe, and China clients.按美国、欧洲和中国客户划分的季度和年度收入数据。
2024-04-29Q1 2024 revenue from US clients RMB 4.90 billion, ex-COVID commercial projects up 0.4% YoY; from European clients RMB 1.07 billion, up 3.9% YoY; from Chinese clients RMB 1.59 billion, down 3.3% YoY.2024年一季度来自美国客户收入49.0亿元，剔除新冠商业化项目同比增长0.4%；来自欧洲客户收入10.7亿元，同比增长3.9%；来自中国客户收入15.9亿元，同比下降3.3%。
2024-07-29WuXi AppTec's revenue from US clients was RMB 10.71 billion in H1 2024, down 1.2% YoY excluding specific commercial production projects. Revenue from China clients was RMB 3.40 billion, up 2.8% YoY. Revenue from European clients was RMB 2.22 billion, up 5.3% YoY.药明康德2024年上半年来自美国客户收入107.1亿元，剔除特定商业化生产项目同比下降1.2%。来自中国客户收入34.0亿元，同比增长2.8%。来自欧洲客户收入22.2亿元，同比增长5.3%。
2025-03-17FY2024 revenue from top 20 global pharma companies reached RMB 16.64B, ex-specific commercial projects +24.1% YoY; US customer revenue RMB 25.02B (+7.7% ex-commercial); European customer revenue RMB 5.23B (+14.4%).2024年全球前20大药企收入166.4亿元，剔除特定商业化项目同比+24.1%；美国客户收入250.2亿元（剔除商业化+7.7%）；欧洲客户收入52.3亿元（+14.4%）。
2025-10-269M 2025 revenue from US customers was RMB 22.15 billion, +31.9% YoY; from China customers RMB 5.04 billion, +0.5% YoY.2025年前三季度来自美国客户收入221.5亿元，同比增长31.9%；来自中国客户收入50.4亿元，同比增长0.5%。
2026-03-23FY2025 US client revenue from continuing ops RMB 31.25B, +34.3% YoY, accounting for >70% of continuing ops revenue.2025年持续经营业务中美国客户收入312.5亿元，同比增长34.3%，占持续经营业务收入逾70%。
2026-03-23FY2025 continuing ops revenue from China clients declined, while US revenue grew 34.3%, increasing US revenue share to >70%.2025年持续经营业务中中国客户收入下滑，美国收入增长34.3%，美国收入占比升至逾70%。
Quality audits & compliance质量审计与合规
2 · 2024-04-30 → 2026-01-14
▾
Disclosed quality and information security audits with 100% pass rates and zero critical findings, including ISO certifications and FDA inspections.披露质量与信息安全审计100%通过率及零重大发现，包括ISO认证和FDA检查。
2024-04-30At Q1 earnings call, disclosed that in 2023 the company underwent 748 quality audits and 83 information security audits from global clients, regulators and third parties, all 100% compliant with no material findings; 24 major operating sites obtained ISO/IEC 27001 certification.一季度业绩会上披露，2023年公司接受了来自全球客户、监管机构和第三方共748次质量审计和83次信息安全审计，均100%合规且无重大发现项；24个主要运营基地获得ISO/IEC 27001认证。
2026-01-14At JPM conference, reported 741 quality audits in 2025 (clients, regulators, third parties) with 100% pass rate and zero critical findings; Changzhou and Taixing sites passed FDA unannounced inspection with zero deficiencies.在JPM大会上报告，2025年累计接受741次质量审计（客户、监管机构、第三方），100%符合要求且无严重发现项；常州和泰兴生产基地以零缺陷通过FDA突击检查。
Earnings calls & guidance业绩电话会与指引
6 · 2024-04-30 → 2026-04-02
▾
Guidance on revenue growth, capex, cash flow, and operational updates from earnings calls and conferences.来自业绩电话会和会议的营收增长、资本开支、现金流及运营更新指引。
2024-04-30At Q1 earnings call, stated CDMO revenue growth slowdown due to delivery-based revenue recognition; full-year CDMO revenue expected to achieve double-digit growth ex-COVID; GLP-1 large orders are long-term contracts.一季度业绩会上表示，CDMO收入增速放缓因基于交付确认收入；全年CDMO收入预期实现剔除新冠双位数增长；GLP-1大订单均为长期合同。
2025-03-172025 guidance: continuing operations revenue to return to double-digit growth of 10%-15%, total revenue expected RMB 41.5B-RMB 43B; 2025 capex RMB 7B-RMB 8B; free cash flow RMB 4B-RMB 5B.2025年指引：持续经营业务收入重回双位数增长（10%-15%），整体收入预计415亿-430亿元；2025年资本开支70亿-80亿元；自由现金流40亿-50亿元。
2025-04-10WuXi AppTec stated at its 2024 results call that US tariff impact is highly uncertain, maintaining its full-year guidance for now.药明康德在业绩说明会上表示美国关税影响极不明朗，暂维持全年指引。
2026-01-15Management at JPM conference guided 2026 organic growth at least comparable to 2025 (reported +16%, continuing ops +21.4%); TIDES revenue expected to grow >40% YoY in 2026; further peptide capacity expansion planned.管理层在JPM大会上展望2026年：内生增长至少与2025年相当（报告口径+16%，持续业务+21.4%）；TIDES业务2026年预计同比增长超40%；计划进一步扩大多肽产能。
2026-03-23FY2026 guidance: total revenue RMB 51.3B-53.0B, continuing ops revenue +18-22% YoY; adjusted free cash flow RMB 10.5B-11.5B; capex RMB 6.5B-7.5B.2026年指引：整体收入513亿-530亿元，持续经营业务收入同比增长18%-22%；经调整自由现金流105亿-115亿元；资本开支65亿-75亿元。
2026-04-02WuXi AppTec announced it will hold its 2025 annual performance briefing on April 13, 2026, via video and online interaction.药明康德公告将于2026年4月13日召开2025年度业绩说明会，采用视频直播和网络互动形式。
Order backlog & client growth在手订单与客户增长
15 · 2024-05-13 → 2026-08-03
▾
Tracking of record order backlogs and expansion of the active client base.追踪创纪录的在手订单和活跃客户群的扩张。
2024-05-13WuXi AppTec disclosed that in Q1 2024 it added over 300 new customers, generating RMB 70 million in revenue from new customers.药明康德披露2024年一季度新增客户超过300家，来自新增客户收入0.7亿元。
2024-07-29As of June 30, 2024, WuXi AppTec's orders in hand reached RMB 43.10 billion, up 33.2% YoY excluding specific commercial production projects. 80% of orders are expected to convert into revenue within the next 18 months.截至2024年6月30日，药明康德在手订单431.0亿元，剔除特定商业化生产项目同比增长33.2%。预计80%订单将在未来18个月内转化为收入。
2024-07-29WuXi AppTec added over 500 new clients in H1 2024, maintaining over 6,000 active clients. Revenue from top 20 global pharma companies reached RMB 6.59 billion, up 11.9% YoY excluding specific commercial production projects.药明康德2024年上半年新增客户超过500家，维持超过6000家活跃客户。来自全球前20大制药企业收入65.9亿元，剔除特定商业化生产项目同比增长11.9%。
2024-08-01As of end-June 2024, WUXI APPTEC's orders in hand reached 43.10 billion yuan, up 33.2% YoY excluding COVID-19 commercial projects.截至2024年6月末，药明康德在手订单金额达431.0亿元，剔除新冠商业化项目后同比增长33.2%。
2024-08-01WUXI APPTEC added over 500 new clients in H1 2024, maintaining over 6,000 active clients.药明康德2024年上半年新增客户超500家，维持超过6000家活跃客户。
2025-01-15At JPM, disclosed that total orders in hand reached RMB 43.82B as of Q3 2024, with a CAGR of 35% since 2018; DM orders CAGR was 55%, now 70% of total backlog.在JPM大会上披露，截至2024年三季度末在手订单达438.2亿元，自2018年以来复合增长率35%；DM订单复合增长率55%，占在手订单总量70%。
2025-02-28WuXi AppTec disclosed that as of end-September 2024, orders in hand were 43.82 billion RMB, up 35.2% YoY; the 2024 annual report will be released on March 18, 2025.药明康德披露截至2024年9月底在手订单438.2亿元，同比增长35.2%；2024年年报将于2025年3月18日披露。
2025-03-17FY2024 ending order backlog for continuing operations was RMB 49.31B, +47% YoY; active customers ~6,000; new customers added ~1,000 in 2024.2024年末持续经营业务在手订单493.1亿元，同比+47%；活跃客户约6000家；2024年新增客户约1000家。
2025-04-28WuXi AppTec's sustained operations order backlog reached RMB 52.33 billion as of March 2025, up 47.1% YoY.截至2025年3月末，药明康德持续经营业务在手订单523.3亿元，同比增长47.1%。
2025-07-28Continuing ops order backlog stood at RMB 56.69B as of June 30, 2025, +37.2% YoY; US client revenue RMB 14.03B, +38.4% YoY.截至2025年6月30日，持续经营业务在手订单566.9亿元，同比增长37.2%；美国客户收入140.3亿元，同比增长38.4%。
2025-10-26Continuing operations orders in hand as of Sep 30, 2025 reached RMB 59.88 billion, +41.2% YoY.截至2025年9月30日，持续经营业务在手订单598.8亿元，同比增长41.2%。
2025-11-20Continuing operations order backlog reached RMB 59.88 billion as of end of Q3 2025, up 41.2% year-on-year.截至2025年三季度末，持续经营业务在手订单规模达598.8亿元，同比增长41.2%。
2026-04-27As of the end of Q1 2026, WuXi AppTec's orders in hand for continuing operations reached 59.77 billion yuan, up 23.6% YoY, a new record high.截至2026年一季度末，药明康德持续经营业务在手订单达到597.7亿元，同比增长23.6%，再创历史新高。
2026-05-01End of Q1 2026, continuing operations order backlog reached RMB 59.77 billion, +23.6% YoY.截至一季度末，持续经营业务在手订单总额597.7亿元，同比增长23.6%。
2026-08-03H1 2026 continuing operations order backlog reached RMB 66.43 billion, up 25.2% YoY; new orders grew over 40% YoY.截至2026年6月末，持续经营业务在手订单664.3亿元，同比增长25.2%；新签订单同比增长超40%。
Fund investments in biotech ventures生物技术风险投资基金投资
6 · 2024-05-22 → 2025-12-18
▾
Commitments to various global biotech and healthcare-focused private equity and venture funds.对多个全球生物技术和医疗保健领域的私募股权和风险基金进行出资。
2024-05-22WuXi AppTec's wholly-owned subsidiary WuXi Fund I committed USD 5 million to LONGWOOD SPECIAL SITUATIONS FUND, L.P., a US-based private equity fund focused on innovative biotech companies, representing about 4.52% of raised capital.药明康德全资子公司WuXi Fund I认缴LONGWOOD SPECIAL SITUATIONS FUND, L.P.私募基金500万美元份额，约占已募集份额的4.52%，该基金专注于创新生物技术企业。
2024-10-25WuXi AppTec's subsidiary WuXi PharmaTech Healthcare Fund I L.P. subscribes SGD 10 million (approx. 7.66% of raised fund shares) in AGP Healthcare Fund VCC, targeting disruptive healthcare businesses in Asia/Southeast Asia.药明康德全资子企业WuXi PharmaTech Healthcare Fund I L.P.认缴AGP Healthcare Fund VCC 1000万新加坡元（约占已募集基金份额的7.66%），该基金主要投资于亚洲/东南亚医疗保健领域的颠覆性业务。
2024-11-15Wholly-owned subsidiary WuXi Fund I subscribed to 10 million euros of Sofinnova Capital XI fund (approx. 4.4% of raised capital), focusing on early-stage life science startups in Europe.全资子企业WuXi Fund I认缴Sofinnova Capital XI基金1000万欧元份额（约占已募集份额的4.4%），专注于欧洲生命科学领域早期初创企业。
2024-12-06WuXi Fund I, a wholly-owned subsidiary of WuXi AppTec, subscribed EUR 20 million (approx. RMB 152 million) for Class A shares of Jeito II S.L.P., a European biopharma early-stage fund managed by Jeito Capital, representing about 5.17% of the fund's raised capital.药明康德全资子企业WuXi Fund I认购Jeito Capital管理的Jeito II S.L.P.基金2000万欧元（约合人民币1.52亿元）A类份额，约占已募集资金的5.17%，该基金专注于欧洲生物制药早期企业。
2024-12-19WuXi Fund I subscribed EUR 10 million (approx. RMB 75 million) each to two Sofinnova Partners funds: SBV II (early-stage biotech creation, ~6.89% stake) and SCO II (growth/late-stage life sciences, ~1.61% stake).WuXi Fund I分别认购Sofinnova Partners旗下SBV II基金（专注欧洲生物科技种子期）和SCO II基金（专注生命科学成长后期）各1000万欧元（约合人民币7500万元），持股比例分别约为6.89%和1.61%。
2025-12-18WuXi Lux Holding subscribed 10 million euros in Jeito II S.L.P. fund (A shares, 1.07% of raised capital) and acquired 20 million euros of fund commitments from WuXi Fund I, totaling 30 million euros (3.22% of raised capital); fund targets early-stage biopharma innovators with global potential.WuXi Lux Holding认购Jeito II S.L.P.基金1000万欧元A类份额（占已募集份额1.07%），并从WuXi Fund I受让2000万欧元认缴份额，合计持有3000万欧元（占已募集份额3.22%）；基金投向具有全球潜力的早期生物医药创新企业。
Singapore R&D & manufacturing base新加坡研发及生产基地
6 · 2024-05-23 → 2026-08-03
▾
Construction and development of the new Singapore campus for global capacity expansion.新加坡新园区用于全球产能扩张的建设和发展。
2024-05-23WuXi AppTec announced the groundbreaking of its R&D and manufacturing base in Singapore, with 7 workshops for small molecules, oligonucleotides, peptides, and complex conjugates; full operation planned for 2027, creating 1,600 jobs.药明康德宣布其新加坡研发及生产基地正式开工建设，设有7个车间用于小分子、寡核苷酸、多肽及复杂偶联药物，计划2027年投入运营，创造1600个就业岗位。
2024-08-01WUXI APPTEC started construction of its R&D and production base in Singapore in May 2024.药明康德于2024年5月在新加坡的研发及生产基地正式开工建设。
2024-10-28WuXi AppTec's Singapore R&D and manufacturing base officially started construction in May 2024; Phase I expected to be operational in 2027.药明康德新加坡研发及生产基地于2024年5月正式开工建设，一期计划于2027年投入运营。
2024-11-29Singapore R&D and manufacturing base officially started construction; planned to begin operations in 2027, expected to create 1,600 jobs upon full completion.新加坡研发及生产基地正式开工建设；计划于2027年投入运营，全面竣工后预计创造1600个就业岗位。
2025-11-03Singapore base officially started construction in early 2024, planned to begin operations from 2027, serving small molecules, oligonucleotides, peptides and complex conjugates.新加坡基地于2024年初正式开工建设，计划于2027年起陆续投入运营，为小分子、寡核苷酸、多肽及复杂偶联药物提供服务。
2026-08-03Approved early start of Changzhou new base construction and accelerated global capacity expansion; Singapore R&D and manufacturing base Phase 1 scheduled to start production in 2027.批准提前启动常州新基地建设，加速全球产能布局；新加坡研发及生产基地一期计划于2027年投产。
Clarifications & corrections澄清与更正
2 · 2024-07-12 → 2025-03-18
▾
Clarified unrelated business relationships and corrected statements about AI drug development and own drug pipelines.澄清无关业务关系，更正关于AI药物研发和自研管线的表述。
2024-07-12WuXi AppTec clarified that WuXi Biologics and Toregem BioPharma's MOU on the USAG-1 monoclonal antibody TRG035 for congenital tooth agenesis is unrelated to WuXi AppTec, as the two are independent companies.药明康德澄清，药明生物与日本Toregem BioPharma就治疗先天性牙齿缺失的USAG-1单抗TRG035签署的合作备忘录与药明康德无关，两家公司独立运营。
2025-03-18Management clarified that WuXi AppTec does not develop its own drugs nor use AI for drug development; the Chemistry42 AI platform belongs to Insilico Medicine, not WuXi AppTec.管理层澄清药明康德不自行开发新药，也未使用AI开发新药；Chemistry42 AI平台属于英矽智能，与药明康德无关。
ESG ratings & sustainability recognitionESG评级与可持续发展认可
15 · 2024-07-19 → 2026-07-06
▾
Consistent high ESG ratings and inclusion in major sustainability indices.持续获得高ESG评级并纳入主要可持续发展指数。
2024-07-19WuXi AppTec was selected for the FTSE4Good Index Series for the second consecutive year, with an ESG score above the global industry standard.药明康德连续第二年入选富时罗素社会责任指数系列（FTSE4Good Index Series），ESG得分高于全球行业标准。
2024-09-02WuXi AppTec received an AA rating in the MSCI ESG assessment for the fourth consecutive year and joined the United Nations Global Compact (UNGC).药明康德连续第四年获得MSCI ESG评级AA级，并加入联合国全球契约组织（UNGC）。
2024-11-13Scored highest in S&P Global CSA 2024, ranking first globally in 'Life Sciences Tools & Services' sector; achieved 43 full marks out of 102 assessment questions.在2024年标普全球CSA中获得行业最高分，位列全球‘生命科学工具与服务’领域第一；102项评估问题中取得43项满分。
2024-11-22Received EcoVadis 2024 Gold Medal with a score of 80/100, ranking in the top 2% of all assessed companies.在2024年EcoVadis企业社会责任评级中获得金牌认证，得分80/100，位列所有参评公司前2%。
2024-12-30WuXi AppTec was selected for the 2024 Dow Jones Sustainability World Index (DJSI World) and Emerging Markets Index (DJSI Emerging Markets) for the fourth consecutive year. It also achieved the highest score in the S&P Global CSA 2024 in the 'Life Sciences Tools & Services' industry.药明康德连续第四年入选2024年道琼斯可持续发展世界指数（DJSI World）和新兴市场指数（DJSI Emerging Markets），并在2024年标普全球CSA评估中获得“生命科学工具与服务”行业最高分。
2025-01-03Selected for the Dow Jones Sustainability World Index (DJSI World) and Emerging Markets Index for the fourth consecutive year; scored highest in 'Life Sciences Tools & Services' sector in S&P Global CSA 2024.连续第四年入选道琼斯可持续发展世界指数和新兴市场指数；在标普全球CSA 2024中获‘生命科学工具与服务’领域最高分。
2025-01-04Named to TIME magazine's 'World's Best Companies in Sustainable Growth 2025' list.入选《时代周刊》‘2025年全球可持续发展最佳企业’榜单。
2025-02-17WuXi AppTec was listed in Time magazine's 'World's Best Companies in Sustainable Growth 2025' for its performance in revenue growth, financial stability, and environmental impact.药明康德荣登《时代周刊》'2025年全球可持续发展最佳企业'榜单，在业绩增长、财务稳健和环境影响方面表现卓越。
2025-04-03WuXi AppTec released its 2024 ESG report, showing a 12.15% reduction in carbon emission intensity and a 36.1% reduction in water use intensity vs 2020 baseline.药明康德发布2024年ESG报告，碳排放强度较2020年基准降低12.15%，用水强度降低36.1%。
2025-06-18WuXi AppTec's greenhouse gas emission reduction targets were certified by the Science Based Targets initiative (SBTi), committing to reduce Scope 1&2 absolute emissions by 42% and Scope 3 by 25% by 2030 vs 2024 base year.药明康德温室气体减排目标通过科学碳目标倡议（SBTi）认证，承诺以2024年为基准，到2030年范围1和2绝对排放量减少42%，范围3减少25%。
2025-07-28MSCI ESG rating upgraded to AAA (first in A-share life-health sector); previously held AA for four consecutive years.MSCI ESG评级升至AAA（A股生命健康行业首家）；此前连续四年保持AA评级。
2025-08-06WuXi AppTec was included in the FTSE4Good Index Series for the third consecutive year, scoring full marks (5/5) in governance, anti-corruption, and labor standards.药明康德连续第三年入选富时罗素社会责任指数系列，在治理、反腐败和劳工标准三项均获满分5分。
2026-06-15London Stock Exchange ESG rating for WuXi AppTec was upgraded to A- from B+; ranked 1st among A-share life science tools and services companies.伦交所ESG评级将药明康德从B+上调至A-；在A股生命科学工具和服务行业中排名第一。
2026-06-23MSCI ESG rating for WuXi AppTec maintained at AAA; ranked 1st among A-share life science tools and services companies.MSCI ESG评级维持药明康德AAA级；在A股生命科学工具和服务行业中排名第一。
2026-07-06WUXI APPTEC received an A- ESG rating from the London Stock Exchange, up from B+ in the previous year.药明康德获得伦交所A-级ESG评级，较上一年B+级上升。
Chemistry (WuXi Chemistry) business performance化学业务（药明化学）业绩
5 · 2024-07-29 → 2026-08-03
▾
Revenue and margin performance of the core chemistry business segment.核心化学业务板块的收入和利润率表现。
2024-07-29WuXi AppTec's Chemistry (WuXi Chemistry) revenue was RMB 12.21 billion in H1 2024, down 9.34% YoY, but up 2.1% excluding specific commercial production projects. Testing revenue was RMB 3.018 billion, down 2.35% YoY. Biology revenue was RMB 1.169 billion, down 5.17% YoY. DDSU revenue was RMB 257 million, down 24.80% YoY. ATU revenue was RMB 575 million, down 19.43% YoY.药明康德化学业务2024年上半年收入122.1亿元，同比下降9.34%，剔除特定商业化生产项目同比增长2.1%。测试业务收入30.18亿元，同比下降2.35%。生物学业务收入11.69亿元，同比下降5.17%。国内新药研发服务部收入2.57亿元，同比下降24.80%。高端治疗CTDMO业务收入5.75亿元，同比下降19.43%。
2024-08-01WUXI APPTEC's chemistry business revenue in H1 2024 was 12.21 billion yuan, down 9.34% YoY; excluding COVID-19 commercial projects, up 2.1% YoY.药明康德化学业务2024年上半年收入122.1亿元，同比下降9.34%；剔除新冠商业化项目后同比增长2.1%。
2026-07-10WUXI APPTEC's chemical business adjusted Non-IFRS gross margin reached 52.8% in Q1 2026, up 5.4 ppts YoY, driven by capacity utilization.2026年第一季度，药明康德化学业务经调整Non-IFRS毛利率提升至52.8%，同比改善5.4个百分点。
2026-08-03H1 2026 chemistry business gross margin improved 7.48 ppts to 56.55%; testing business gross margin improved 11.32 ppts.2026年上半年化学业务毛利率提升7.48个百分点至56.55%；测试业务毛利率提升11.32个百分点。
2026-08-03H1 2026 chemistry business gross margin improved 7.48 ppts to 56.55%; testing business gross margin improved 11.32 ppts.2026年上半年化学业务毛利率提升7.48个百分点至56.55%；测试业务毛利率提升11.32个百分点。
Pricing & market dynamics定价与市场动态
2 · 2024-07-30 → 2024-09-27
▾
Discussed dynamic pricing strategies, price stability, and competitive positioning across client segments and geographies.讨论跨客户群和地区的动态定价策略、价格稳定性及竞争定位。
2024-07-30WuXi AppTec stated at the H1 results briefing that its pricing strategy is dynamic and flexible by segment and client group. Overseas prices are stabilizing, while domestic prices use dynamic pricing to cope with competition. Chemistry business prices remained stable YoY.药明康德在中期业绩交流会上表示，公司针对不同板块和客户群体制定动态灵活的价格策略。海外价格趋于稳定，国内订单以动态定价应对竞争。化学业务价格与去年保持稳定。
2024-09-27CCB International reported that 3 of 14 small-molecule new drugs approved by the U.S. FDA in H1 2024 were manufactured by WuXi AppTec; management expects 3-5 small-molecule commercial projects to be approved in H2 2024.建银国际报告称，2024年上半年美国FDA批准的14种小分子新药中，3种由药明康德生产；管理层预计2024年下半年将有3-5个小分子商业项目获批。
Workforce & organizational changes人力与组织变动
2 · 2024-07-30 → 2024-08-01
▾
Employee count changes, hiring trends, and organizational optimization efforts.员工人数变化、招聘趋势和组织优化举措。
2024-07-30WuXi AppTec stated at the H1 results briefing that employee numbers decreased by 2,982 to 38,134 as of June 30, 2024, due to organizational optimization and automation improvements. TIDES business added over 500 employees in H1 and is expected to exceed 2,000 by year-end.药明康德在中期业绩交流会上表示，截至2024年6月30日员工人数减少2982人至38134人，原因是组织优化和自动化提升。TIDES业务上半年新增500多人，预计年底增至2000人以上。
2024-08-01WUXI APPTEC's employee count decreased by nearly 3,000 in H1 2024, to 38,134 from 41,116 at end-2023.药明康德2024年上半年减员近3000人，员工总数从2023年末的41,116人降至38,134人。
Domestic new drug R&D service (DDSU)国内新药研发服务（DDSU）
1 · 2024-08-01
▾
Declining revenue trend in the domestic new drug R&D service business.国内新药研发服务业务的收入下降趋势。
2024-08-01WUXI APPTEC's domestic new drug R&D service revenue in H1 2024 was 257 million yuan, down 24.8% YoY.药明康德国内新药研发服务部2024年上半年收入2.57亿元，同比下降24.8%。
R&D & capex trends研发与资本开支趋势
8 · 2024-08-01 → 2026-04-24
▾
Declining R&D expenses and headcount, increasing capital expenditure, and technology-driven synthesis cycle improvements.研发费用和人员下降，资本开支增加，技术驱动的合成周期缩短。
2024-08-01WUXI APPTEC plans to increase DM capital expenditure by over 50% YoY in 2025.药明康德预计2025年DM资本开支同比增长超50%。
2024-11-22Company expects 2024 capex around 4 billion yuan; 2025 capex for DM business to grow over 50% YoY.公司预计2024年资本开支约40亿元；2025年DM业务资本开支同比增长超50%。
2025-01-15At JPM, guided that DM (development & manufacturing) capital expenditure will double in 2025; 6 sites globally under construction, 5 with DM capabilities.在JPM大会上指引，2025年DM资本支出将翻番；全球有6个在建基地，其中5个具备DM能力。
2025-07-28Planned 2025 capex of RMB 7-8B; small molecule API reactor total volume to exceed 4,000kL by end of 2025; US site to be operational by end of 2026.计划2025年资本开支70-80亿元；预计2025年底小分子原料药反应釜总体积超4000kL；美国基地将于2026年末投入运营。
2026-03-23FY2025 capex RMB 5.54B; FY2026 capex guided RMB 6.5B-7.5B for global capacity expansion including TIDES and overseas sites.2025年资本开支55.4亿元；2026年资本开支指引65亿-75亿元，用于TIDES及海外产能扩张。
2026-04-03WuXi AppTec's R&D expenses fell for three consecutive years to 1.119 billion yuan in 2025, down about 30% from the 2022 peak. R&D personnel decreased to 25,983, a reduction of about 30% from 36,678 in 2022.药明康德研发费用连降三年，2025年降至11.19亿元，较2022年高点缩减约30%。研发人员从2022年的36678人降至25983人，减少约30%。
2026-04-03WuXi AppTec's capital expenditure in 2025 increased by over 1.5 billion yuan YoY, an increase of 38%.药明康德2025年资本支出较上年增长逾15亿元，增幅达38%。
2026-04-24WuXi AppTec announced it successfully shortened the synthesis cycle of a key drug intermediate from an estimated 4+ months to 10 weeks by integrating photochemistry and other advanced technologies, achieving rapid preparation at the hundred-gram scale and above.药明康德宣布通过整合光化学等前沿技术，成功将一项关键药物中间体的合成周期从预估的4个多月缩短至10周，并实现了百克级以上规模的精准快速制备。
Cash flow & financial metrics现金流与财务指标
2 · 2024-08-01 → 2026-03-23
▾
Operating cash flow performance and non-recurring gains from divestitures.经营现金流表现和资产处置的非经常性收益。
2024-08-01WUXI APPTEC's operating cash flow in H1 2024 was 4.966 billion yuan, down 11.29% YoY; excluding COVID-19 projects, operating cash flow grew 48.3% YoY.药明康德2024年上半年经营活动现金流净额49.66亿元，同比下降11.29%；剔除新冠项目后同比增长48.3%。
2026-03-23FY2025 non-recurring gain from sale of WuXi XDC Cayman stake and business divestitures contributed significantly to net profit.2025年出售药明合联部分股权及剥离业务的非经常性收益对净利润贡献显著。
Product approvals & milestones产品批准与里程碑
2 · 2024-08-09 → 2026-05-07
▾
FDA approvals of drugs manufactured by WuXi AppTec and PROTAC development milestones.药明康德生产的药物获FDA批准及PROTAC开发里程碑。
2024-08-09Citius Pharmaceuticals announced FDA approval of Lymphir (denileukin diftitox), a drug manufactured by WUXI APPTEC, for r/r CTCL.Citius Pharmaceuticals宣布FDA批准Lymphir（denileukin diftitox）上市，该药由药明康德生产，用于治疗复发/难治性皮肤T细胞淋巴瘤。
2026-05-07Supported development of over 120 PROTAC molecules, with more than 20 in clinical stage; milestone of first global PROTAC drug entering clinical use.已支持超过120款PROTAC分子开发，其中逾20个进入临床阶段；全球首个PROTAC药物进入临床应用里程碑。
H-share reward trust plansH股奖励信托计划
8 · 2024-09-24 → 2026-04-01
▾
Recurring H-share purchase and grant programs under reward trust plans to incentivize employees.根据奖励信托计划定期购买和授予H股以激励员工。
2024-09-24WuXi AppTec completed the purchase of HKD 1 billion in H-shares under the 2024 H-share Reward Trust Plan, buying 27.48 million shares (0.94% of total shares), contingent on achieving 2024 revenue of at least RMB 38.3 billion.药明康德完成2024年H股奖励信托计划下10亿港元的H股购买，购入2747.84万股（占总股本0.94%），条件为2024年营收达到383亿元或以上。
2025-01-10Granted 100,000 H股 reward shares to 17 selected participants under the 2022 H-share Reward Trust Plan; shares purchased via on-market trades, no dilution.根据2022年H股奖励信托计划，向17名选定参与者授予10万股H股奖励股份；股份通过场内交易购入，无稀释效应。
2025-03-17Proposed 2025 H-share incentive trust plan: if 2025 revenue reaches RMB 42B, grant HKD 1.5B in H-shares; if revenue reaches RMB 43B or above, grant an additional HKD 1B in H-shares.拟推出2025年H股奖励信托计划：若2025年营收达420亿元，授予15亿港元H股；若达430亿元及以上，额外授予10亿港元H股。
2025-05-22Granted 27,274,870 H-share awards (0.94% of total shares) to 3,985 participants under the 2024 H-share Reward Trust Plan, including 3,218,074 shares to connected persons; vesting in four tranches from Dec 2025.根据2024年H股奖励信托计划，向3985名参与者授予2727.487万股H股奖励（占总股本0.94%），其中关联人士获授321.8074万股；分四期归属，自2025年12月起。
2025-06-13WuXi AppTec completed the purchase of 21,105,089 H-shares for HKD 1.5 billion under the 2025 H-share Reward Trust Plan, contingent on achieving 2025 revenue of at least RMB 42 billion.药明康德完成2025年H股奖励信托计划下15亿港元H股购买（21,105,089股），以2025年营收达420亿元为授予条件。
2025-06-30WuXi AppTec completed the full HKD 2.5 billion H-share purchase under the 2025 H-share Reward Trust Plan, covering both basic and additional grant conditions, totaling 34.093 million H-shares.药明康德完成2025年H股奖励信托计划下合计25亿港元H股购买，覆盖基本及附加授予条件，共购入3409.3万股H股。
2025-07-10Completed H-share reward trust plan: total HK$2.5B used to buy 12,987,886 H-shares (basic + additional conditions); additional condition requires 2025 revenue >= RMB 43B.完成H股奖励信托计划：合计使用25亿港元购买12,987,886股H股；附加授予条件为2025年营收达到或超过430亿元。
2026-04-01WuXi AppTec's 2.5 billion HKD H-share reward trust plan is set to be unlocked due to 'exceeding expectations' in 2025 performance, used to incentivize and retain core talent.药明康德25亿港元的H股奖励信托计划因2025年业绩‘超预期’将正式解锁，用于激励和保留核心人才。
Convertible bonds issuance & conversion可转换债券发行与转换
8 · 2024-10-08 → 2026-05-21
▾
Issuance of USD and RMB zero-coupon convertible bonds and their subsequent conversion into H-shares.发行美元和人民币零息可转换债券及其后续转换为H股。
2024-10-08WuXi AppTec announces issuance of USD 500 million zero-coupon guaranteed convertible bonds due 2025, with initial conversion price of HKD 80.02 per H-share, net proceeds of approximately USD 494.4 million for global business development, debt refinancing, and general corporate purposes.药明康德宣布发行5亿美元零息有担保可转换债券（2025年到期），初始转股价每股H股80.02港元，募集资金净额约4.944亿美元，用于全球业务发展、债务再融资及一般公司用途。
2024-10-21WuXi AppTec completes issuance of USD 500 million zero-coupon guaranteed convertible bonds due 2025; listing and trading on HKEX approved effective Oct 22.药明康德完成5亿美元零息有担保可转换债券（2025年到期）的发行；港交所上市及交易批准于10月22日生效。
2025-05-23Adjusted conversion price of USD 500 million zero-coupon guaranteed convertible bonds due 2025 from HKD 80.02 to HKD 78.28 per H-share, effective May 24, 2025, due to dividend distribution.因分红派息，将5亿美元2025年到期零息有担保可转换债券的转股价由每股H股80.02港元调整为78.28港元，自2025年5月24日起生效。
2025-08-25WuXi AppTec converted 7.8369 million H-shares from its USD 500 million zero-coupon guaranteed convertible bonds due 2025.药明康德因5亿美元2025年到期的零息有担保可转换债券转换而发行783.69万股H股。
2025-10-08Converted USD 500M zero-coupon guaranteed convertible bonds due 2025 into 14,185,818 H-shares at adjusted conversion price of HKD 78.28 per share; total H-shares increased to 492,412,308.将5亿美元2025年到期的零息有担保可转换债券按经调整转换价每股78.28港元转换为14,185,818股H股；H股总数增至492,412,308股。
2025-11-05Completed conversion of USD 500 million zero-coupon guaranteed convertible bonds into H-shares; all outstanding bonds converted by Oct 10, 2025, and bond listing cancelled on Oct 20, 2025.完成5亿美元零息有担保可转换债券的转股程序；所有未偿还债券已于2025年10月10日全部转换为H股，债券上市地位于2025年10月20日撤销。
2026-05-15Issued RMB 6.78 billion zero-coupon convertible bonds due 2027 (USD-settled), initial conversion price HKD 153 per H-share, ~17.6% premium. Net proceeds ~USD 1.023 billion, 90% for global capacity expansion.发行67.8亿元人民币2027年到期的美元结算零息可转换债券，初始转股价每股H股153港元，溢价约17.6%。所得款项净额约10.23亿美元，90%用于全球产能扩张。
2026-05-21Completed issuance of RMB 6.78 billion convertible bonds; net proceeds ~USD 1.023 billion; bonds listed on Vienna Stock Exchange pending approval; conversion shares approved for HKEX listing.完成67.8亿元可转债发行；所得款项净额约10.23亿美元；债券在维也纳证券交易所上市待批；转换股份获港交所上市批准。
New facility openings & R&D centers新设施启用与研发中心
1 · 2024-11-15
▾
Opening of new R&D centers and facilities in Changzhou and other locations.在常州等地启用新的研发中心与设施。
2024-11-15New R&D center in Changzhou, Jiangsu officially opened, covering 134,000 sqm, enhancing capabilities in small molecules, oligonucleotides, peptides, and complex chemical conjugates.位于江苏常州的全新研发中心正式启用，占地13.4万平方米，提升小分子、寡核苷酸、多肽及复杂化学偶联药物开发能力。
Strategic partnerships & collaborations战略合作伙伴关系
4 · 2025-01-03 → 2025-10-28
▾
Key partnerships including Saudi NEOM, Johnson & Johnson, and supply chain initiatives.包括沙特NEOM、强生以及供应链倡议在内的关键合作伙伴关系。
2025-01-03Joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partnership member.加入制药供应链倡议（PSCI），成为供应商合作伙伴。
2025-02-27WuXi AppTec announced it has officially joined the Pharmaceutical Supply Chain Initiative (PSCI) as a supplier partner.药明康德宣布正式加入制药供应链倡议（PSCI），成为PSCI供应商合作伙伴。
2025-07-22Partnered with Johnson & Johnson and Protagonist Therapeutics to submit NDA to US FDA for oral peptide icotrokinra (JNJ-2113) for moderate-to-severe plaque psoriasis.与强生、Protagonist Therapeutics共同向美国FDA提交口服多肽icotrokinra（JNJ-2113）治疗中重度斑块状银屑病的新药上市申请。
2025-10-28Signed strategic cooperation memoranda with Saudi NEOM and Ministry of Health to explore localizing drug R&D and manufacturing in Saudi Arabia, potentially establishing a CRDMO base in Oxagon or other regions.与沙特新未来城(NEOM)和沙特卫生部签署战略合作备忘录，探索在沙特开展新药研发与生产服务本地化，可能在Oxagon或其他地区建立CRDMO基地。
WuXi XDC stake sales药明合联股权出售
6 · 2025-01-13 → 2026-01-12
▾
Multiple block trades reducing WuXi AppTec's stake in WuXi XDC, generating significant investment gains.多次大宗交易减持药明合联股份，产生可观投资收益。
2025-01-13Cumulatively sold 86 million shares of WuXi XDC (药明合联) via two block trades (Nov 8, 2024 & Jan 10, 2025), representing 7.17% of WuXi XDC's total shares, for approx. HK$2.426 billion; realized investment gain of RMB 2.016 billion over past 12 months, impacting 2024 net profit by ~RMB 720M and 2025 net profit by ~RMB 1.297B.通过两次大宗交易（2024年11月8日及2025年1月10日）累计出售药明合联8600万股，占其总股本7.17%，成交金额约24.26亿港元；过去12个月实现投资收益20.16亿元，影响2024年净利润约7.20亿元、2025年净利润约12.97亿元。
2025-01-13Announced at JPM that proceeds from WuXi XDC sale will be used to accelerate global capacity and capability buildout, strengthen the integrated CRDMO model.在JPM大会上宣布，出售药明合联所得现金将用于加速全球产能及能力建设，强化一体化CRDMO模式。
2025-04-01WuXi AppTec sold 50.8 million shares of WuXi XDC via block trade for approx. HK$2.178 billion, recording an investment gain of about RMB 1.847 billion.药明康德通过大宗交易出售药明合联5080万股，成交金额约21.78亿港元，投资收益约18.47亿元。
2025-10-08Sold 30.3 million shares of WuXi XDC (2268.HK) via block trade for approx. HKD 2.346 billion, reducing stake to below 2.47% of WuXi XDC's total shares; cumulative 2025 net investment gain impact on net profit is approx. RMB 4.351 billion.通过大宗交易出售药明合联(2268.HK)3030万股，成交金额约23.46亿港元，持股比例降至药明合联总股本2.47%以下；2025年累计出售股票的投资净收益对净利润影响约43.51亿元。
2025-11-01Sold 30.3 million shares of WuXi XDC (药明合联) on Oct 8, 2025, for approx. HKD 2.346 billion, with a net profit impact of RMB 1.679 billion on 2025 after-tax net profit.2025年10月8日出售药明合联3030万股，成交金额约23.46亿港元，对2025年度税后净利润影响约16.79亿元。
2026-01-12Non-recurring gains of ~5.60 billion yuan from selling part of WuXi XDC Cayman Inc. equity (net gain ~4.16 billion yuan) and 100% of Shanghai康德弘翼 and Shanghai药明津石 (net gain ~1.43 billion yuan).非经常性损益合计约55.95亿元，主要来自出售药明合联部分股权（净收益约41.61亿元）以及出售上海康德弘翼医学临床研究有限公司和上海药明津石医药科技有限公司100%股权（净收益约14.34亿元）。
GLP-1 drug platform supportGLP-1药物平台支持
3 · 2025-01-15 → 2026-07-10
▾
Growing support for clinical-stage GLP-1 drugs, establishing a leading market share.对临床阶段GLP-1药物的支持不断增长，确立了领先的市场份额。
2025-01-15At JPM, disclosed that as of end-2024, the company supported 20 clinical-stage GLP-1 drugs (up 54% YoY), vs 85 globally (up 37% YoY).在JPM大会上披露，截至2024年末，公司支持的临床阶段GLP-1药物数量达20个（同比增长54%），全球同期为85个（同比增长37%）。
2026-03-23FY2025 GLP-1 drug support: 24 drugs, 15 in late-stage clinical; ~25% share of global clinical-stage GLP-1 market.2025年支持24款GLP-1药物，其中15款进入后期临床；占全球临床阶段GLP-1市场约25%份额。
2026-07-10WUXI APPTEC supported 12 of 36 small-molecule GLP-1 drugs, 11 of 56 peptide GLP-1 drugs, and 1 of 7 commercialized GLP-1 drugs in global clinical trials.在全球临床阶段GLP-1药物中，药明康德支持了36个小分子药物中的12个、56个多肽药物中的11个、7个已商业化药物中的1个。
US medical device testing divestiture美国医疗器械测试业务剥离
2 · 2025-01-17 → 2025-11-03
▾
Sale of the US medical device testing business to NAMSA.将美国医疗器械测试业务出售给NAMSA。
2025-01-17Sold US medical device testing business (two facilities in Atlanta, GA and St. Paul, MN) to NAMSA; financial terms not disclosed.将美国医疗器械测试业务（佐治亚州亚特兰大和明尼苏达州圣保罗的两个工厂）出售给NAMSA；财务细节未披露。
2025-11-03Sold US medical device testing business in January 2025.2025年1月出售美国医疗器械测试业务。
Minority investments & stakes少数股权投资与持股
4 · 2025-02-17 → 2026-07-29
▾
Transactions and updates related to minority stakes in Hanbon Technology and other portfolio companies, including sales and listings.与汉邦科技等被投企业少数股权相关的交易和更新，包括出售和上市。
2025-02-17WuXi AppTec sold its 916,667 shares in Hanbon Technology (IPO applicant) for 50 million RMB to Huajin Lingyue in March 2023; Hanbon's IPO prospectus removed a 291 million RMB working capital supplement item.药明康德于2023年3月以5000万元将其持有的汉邦科技91.6667万股股份转让给华金领越；汉邦科技IPO上会稿删除了2.91亿元补流项目。
2025-05-18Portfolio company Jiangsu Hanbon Science & Technology (688755.SH) listed on Shanghai Stock Exchange on May 16, 2025; WuXi AppTec indirectly holds 6.04% stake, classified as FVTPL financial asset with immaterial current impact.参股公司江苏汉邦科技（688755.SH）于2025年5月16日在上交所上市；药明康德间接持有6.04%股份，分类为以公允价值计量且变动计入当期损益的金融资产，当前影响不重大。
2026-07-03Shanghai WUXI APPTEC plans to reduce its stake in Hanbon Technology by up to 1.144 million shares (1% of total shares) from July 27 to October 26, 2026.上海药明康德计划在2026年7月27日至10月26日期间减持汉邦科技不超过114.40万股（占总股本1%）。
2026-07-29WUXI APPTEC completed a block trade of 463,700 shares at RMB 126.5 per share, totaling RMB 58.6642 million.药明康德完成一笔大宗交易，涉及46.37万股，成交价126.5元/股，总金额5866.42万元。
Research institutes & subsidiaries研究院与子公司
4 · 2025-02-17 → 2025-10-28
▾
Establishment, restructuring, and capital changes of subsidiaries and research entities, including SynTheAll transfer and capital reductions.子公司和研究实体的设立、重组和资本变动，包括合全药业转让和减资。
2025-02-17WuXi AppTec's subsidiary Shanghai WuXi ATU Medical Technology Co., Ltd. increased registered capital from 100 million RMB to 600 million RMB (500% increase); original parent Wuxi Shengji Medical Technology exited, and WuXi AppTec became the direct sole shareholder.药明康德子公司上海药明生基医药科技有限公司注册资本由1亿元增至6亿元（增幅500%）；原全资股东无锡生基医药科技有限公司退出，药明康德成为直接全资股东。
2025-06-10WuXi AppTec established a wholly-owned subsidiary, WuXi AppTec (Shanghai) Pharmaceutical R&D Co., Ltd., with registered capital of RMB 5 million, for medical research and development.药明康德全资设立药明康德（上海）医药研发有限公司，注册资本500万元，从事医学研究和试验发展。
2025-09-02WuXi AppTec announced the transfer of 98.9% of Shanghai SynTheAll Pharmaceutical Co., Ltd. shares to newly established WuXi R&D to optimize organizational structure.药明康德宣布将上海合全药业股份有限公司98.9%的股份划转至新设的药明研发，以优化组织结构。
2025-10-28Shanghai WuXi AppTec's registered capital reduced from approx. RMB 12.46 billion to approx. RMB 2.58 billion, a decrease of about 79%.上海药明康德新药开发有限公司注册资本由约124.6亿元减至约25.8亿元，降幅约79%。
Global expansion & green initiatives全球扩张与绿色倡议
3 · 2025-02-17 → 2025-11-03
▾
Overseas site expansions, green electricity agreements, and sustainability efforts.海外基地扩张、绿色电力协议和可持续发展举措。
2025-02-17WuXi AppTec's Suzhou base signed a multi-year green electricity bilateral negotiation transaction letter of intent with Jiangsu Lidian Energy Sales Co., Ltd., directly purchasing wind power from Inner Mongolia for 5 years, marking Jiangsu's first multi-year green electricity transaction.药明康德苏州基地与江苏利电能源销售有限公司签订多年期绿色电力双边协商交易意向书，直接采购内蒙古风电项目绿电，为期5年，标志着江苏首笔多年期绿电交易落地。
2025-03-18Overseas capacity expansion: Switzerland Kuppersbusch site oral solid dosage capacity doubled in 2024; Singapore R&D and manufacturing base broke ground in May 2024, Phase I expected to start operations in 2027; Taixing API production base commenced operations in 2024.海外产能扩建：瑞士库威基地2024年口服制剂产能翻倍；新加坡研发及生产基地2024年5月开工，一期计划2027年投运；泰兴原料药生产基地2024年投入运营。
2025-11-03Swiss Kuevi (库威) site: oral-dosage packaging capacity doubled in 2024; spray-drying workshop broke ground in 2025, expected completion in Q4 2026.瑞士库威基地：口服剂型包装产能已于2024年翻倍；喷雾干燥车间于2025年破土动工，预计2026年四季度竣工。
Capital management & treasury资本管理与资金运作
4 · 2025-03-18 → 2026-03-23
▾
Board approvals for cash management, forex hedging, auditor reappointment, and guarantee provisions for subsidiaries.董事会批准现金管理、外汇对冲、审计师续聘及子公司担保。
2025-03-18Proposed 2025 guarantee of up to RMB 11.5B (or equivalent in foreign currency) for subsidiaries within consolidated scope, to be submitted for shareholder approval.拟在2025年度为合并报表范围内下属子企业提供不超过115亿元人民币或其他等值外币的担保，尚需股东大会批准。
2026-03-23Board approved use of up to RMB 18.0B idle自有资金 for cash management (low-risk products).董事会批准使用不超过180亿元闲置自有资金进行现金管理（低风险产品）。
2026-03-23Board approved FY2026 forex hedging with max daily contract value of USD 9.0B equivalent.董事会批准2026年度外汇套期保值业务，任一交易日最高合约价值不超过90亿美元等值。
2026-03-23Board approved reappointment of Deloitte Touche Tohmatsu (domestic) and Deloitte Touche Tohmatsu (overseas) as FY2026 auditors.董事会批准续聘德勤华永（境内）和德勤·关黄陈方（境外）为2026年度审计机构。
Executive leadership changes高管领导层变动
4 · 2025-03-30 → 2026-07-01
▾
Retirement and appointment of key executives including the Vice Chairman and Board Secretary.包括副董事长和董事会秘书在内的关键高管退休与任命。
2025-03-30Vice Chairman Hu Zhengguo will retire on July 31, 2025, resigning from positions including director, vice chairman, global chief investment officer, and CEO of ATU business.副董事长胡正国将于2025年7月31日退休，辞去董事、副董事长、全球首席投资官、高端治疗事业部首席执行官等职务。
2025-04-02WuXi AppTec Vice Chairman Hu Zhengguo announced retirement effective July 31, 2025, after 18 years of service.药明康德副董事长胡正国宣布将于2025年7月31日退休，届时辞去所有现任职务。
2025-07-28Board secretary Zhang Yuanzhou resigned; Han Min appointed as new board secretary and company secretary.董事会秘书张远舟辞职，聘任韩敏为新任董事会秘书及公司秘书。
2026-07-01WUXI APPTEC held the 4th board meeting and approved the replacement of the company secretary.药明康德召开第四届董事会第四次会议，审议通过更换公司秘书的议案。
Regulatory & legal affairs监管与法律事务
2 · 2025-07-15 → 2025-08-07
▾
Fines, regulatory communications, and seminars related to compliance and regulatory requirements.与合规和监管要求相关的罚款、监管沟通和研讨会。
2025-07-15Tianjin subsidiary fined for failing to implement emergency plan materials and equipment; penalty waived due to timely rectification and no actual harm.天津全资子公司因未落实应急预案规定的应急物资及装备被查处，因及时整改且未造成实际危害，不予行政处罚。
2025-08-07WuXi AppTec's Testing Division held a seminar on Sino-US NDA regulatory communication and submission requirements.药明康德测试事业部举办中美新药上市申请（NDA）监管沟通与申报要求研讨会。
Analyst ratings & target prices分析师评级与目标价
3 · 2025-08-04 → 2026-06-30
▾
Brokerage upgrades, target price revisions, and positive analyst commentary.券商上调评级、目标价调整和积极的分析师评论。
2025-08-04BOCI raised WuXi AppTec's target price from HKD 81 to HKD 122, maintaining 'Buy', after raising 2025-2026 EPS forecasts by 15% and 22% respectively.中银国际将药明康德目标价从81港元上调至122港元，维持“买入”评级，上调2025-2026年每股盈利预测15%和22%。
2025-08-05Bank of America Securities raised WuXi AppTec's H-share target price to HKD 123 and A-share target price to RMB 114.4, reiterating 'Buy', citing robust order growth and operational efficiency.美银证券将药明康德H股目标价上调至123港元，A股目标价上调至114.4元，重申“买入”评级，理由为订单增长稳健及运营效率提升。
2026-06-30Morgan Stanley raised WuXi AppTec H-share target price to HKD 168 (from HKD 155) and A-share target price to RMB 153 (from RMB 145), reiterating 'Overweight' and naming it a top pick; raised 2026-2028 adjusted EPS forecasts by 4%-6%.摩根士丹利将药明康德H股目标价从155港元上调至168港元，A股目标价从145元上调至153元，重申'增持'并列为首选股；上调2026-2028年调整后盈利预测4%-6%。
Related-party transactions关联交易
2 · 2025-09-02 → 2025-10-16
▾
Supplementary agreements and framework contracts for related-party services, including payload-linker services and technical service contracts.关联方服务的补充协议和框架合同，包括payload-linker服务和技术服务合同。
2025-09-02WuXi AppTec signed a supplementary agreement with XDC Cayman to raise the 2025 related-party transaction cap for payload-linker services from 168M to 200M RMB, and a new 3-year framework agreement (2026-2028) with annual caps of 300M, 400M, and 400M RMB.药明康德与XDC开曼签署补充协议，将2025年度有效载荷连接子关联交易额度从1.68亿元提升至2亿元，并签署新的三年期框架协议（2026-2028年），年度上限分别为3亿元、4亿元和4亿元。
2025-10-16Signed a technical service contract with Buchang Pharmaceutical's subsidiary Luzhou Buchang for pharmacokinetics and toxicology testing, total contract value RMB 10.8 million (incl. tax).与步长制药子公司泸州步长签订药代动力学和毒理学试验技术服务合同，合同总金额1080万元（含税）。
Clinical CRO & SMO divestiture临床CRO与SMO业务剥离
4 · 2025-10-26 → 2025-12-15
▾
Sale of Kangde Hongyi and Jinshi Medical clinical services businesses to Hillhouse.将康德弘翼和药明津石临床服务业务出售给高瓴。
2025-10-26Subsidiary Shanghai WuXi plans to sell 100% equity of Kangde Hongyi (clinical CRO) and JinShi Medical (SMO) to Hillhouse-investment entities for a base consideration of RMB 2.8 billion, to focus on CRDMO core business.全资子公司上海药明拟以28亿元基准对价向高瓴投资旗下实体转让康德弘翼（临床CRO）和津石医药（SMO）100%股权，以聚焦CRDMO核心业务。
2025-11-07Agreed to sell 100% equity of its clinical CRO and SMO businesses (康德弘翼 and 药明津石) to Hillhouse Capital (高瓴投资) for RMB 2.8 billion.与高瓴投资达成协议，拟以28亿元出售中国临床服务研究业务100%股权，包括临床CRO和SMO业务（康德弘翼和药明津石）。
2025-12-03Hillhouse Capital completed full acquisition of Nanjing Mingjie Bio-Test (Mingjie Pharma), a former WuXi AppTec subsidiary focused on drug quality research, following its ~2.8 billion yuan purchase of Kangde Hongyi and Jinshi Medicine in October.高瓴资本完成对原药明康德子公司南京明捷生物检测（明捷医药）的全资收购，该公司专注于药物质量研究；此前10月高瓴以约28亿元收购康德弘翼和津石医药。
2025-12-15WuXi AppTec completed the sale of 100% equity in Shanghai Kangde Hongyi Medical Clinical Research and Shanghai WuXi Jinshi Medical Technology for 2.8 billion yuan, receiving first installment of 1.54 billion yuan; expected after-tax net profit of ~960 million yuan (>10% of 2024 audited net profit).药明康德完成出售上海康德弘翼医学临床研究和上海药明津石医药科技100%股权，对价28亿元，已收到首期15.4亿元；预计产生税后净利润约9.6亿元（占2024年经审计归母净利润超10%）。
Operational metrics & capacity运营指标与产能
5 · 2026-01-14 → 2026-08-03
▾
Compound synthesis volumes, molecule progression, reactor capacities, and site expansions.化合物合成量、分子进展、反应器产能和基地扩张。
2026-01-14At the 44th J.P. Morgan Healthcare Conference, disclosed that small-molecule API reactor capacity reached 4 million liters by end-2025; peptide solid-phase synthesis reactor capacity exceeded 100,000 liters; GLP lab area >120,000 sqm.在第44届摩根大通医疗健康大会上披露：截至2025年底小分子原料药反应釜总体积达400万升；多肽固相合成反应釜总体积超10万升；GLP实验室面积超12万平方米。
2026-04-07WuXi AppTec highlighted its over 100,000 liters of peptide synthesis capacity and over 4 million liters of small-molecule reactor capacity, positioning itself as a key enabler for GLP-1 drug development across both peptide and small-molecule modalities.药明康德强调其拥有超过10万升多肽合成产能和超过400万升小分子反应釜产能，定位为赋能GLP-1药物在多肽和小分子两种技术路径上开发的核心引擎。
2026-05-18In 2025, synthesized over 420,000 new compounds in drug discovery stage; advanced 310 molecules into process development.2025年在药物发现阶段合成了超42万个新化合物，成功将310个分子推入工艺开发阶段。
2026-05-18Small molecule reactor capacity exceeded 4 million liters; peptide solid-phase synthesis capacity exceeded 100,000 liters, enabling large-scale commercial production for GLP-1 and peptide drugs.小分子反应釜产能超400万升；多肽固相合成产能超10万升，支持GLP-1和多肽药物大规模商业化生产。
2026-08-03H1 2026 small-molecule R (discovery) delivered over 440,000 new compounds; R-to-D conversion reached 155 molecules.2026年上半年小分子药物发现（R）业务成功合成并交付超44万个新化合物；R到D转化分子155个。
Other developments其他动态
1 · 2026-01-14
▾
Assorted one-off developments.零散的一次性动态。
2026-01-14At JPM conference, disclosed that from 2011 to 2025, served over 9,000 preclinical clients and established long-term partnerships with all top 20 global pharma companies; global network includes >20 R&D and manufacturing sites across Asia, Europe, and North America.在JPM大会上披露，2011年至2025年累计服务超9000家临床前客户，与全球前20大药企全部建立长期合作；全球网络覆盖亚洲、欧洲和北美超20个研发与生产基地。
Employee incentives & compensation员工激励与薪酬
3 · 2026-03-23 → 2026-08-03
▾
Cash incentive plans, salary adjustments, employee stock ownership plans, and H-share reward trust plans.现金激励计划、薪酬调整、员工持股计划和H股奖励信托计划。
2026-03-23Proposed H-share reward trust plan of up to HKD 2.5B, tied to FY2026 revenue targets (RMB 51.3B base, RMB 53.0B stretch).拟设立最高25亿港元H股奖励信托计划，与2026年营收目标挂钩（基本目标513亿元，附加目标530亿元）。
2026-04-01WuXi AppTec disclosed that it has implemented a comprehensive cash incentive plan, including a year-end bonus, a 'universal sunshine award' of 2,500 yuan per person for two consecutive times, and a special salary adjustment for chemical platform employees with an average increase of 12%.药明康德披露已实施全面现金激励计划，包括年终奖、连续两次向全员发放人均2500元的‘阳光普照奖’，以及针对化学平台员工的专项普调，平均调薪幅度达12%。
2026-08-03Launched 2026 A-share employee stock ownership plan for up to 4,000 managers and core technical staff, covering up to 9.70 million shares at RMB 103.08/share, funded by a long-term incentive fund of up to RMB 1 billion.发布2026年A股员工持股计划草案，拟向不超过4000名管理人员及核心技术骨干授予不超过970.12万股，购买价格103.08元/股，资金来源为长期激励基金，合计不超过10亿元。
Shareholder structure & market performance股东结构与市场表现
3 · 2026-04-01 → 2026-05-01
▾
Institutional holdings changes, share price movements, and market capitalization updates.机构持股变动、股价波动和市值更新。
2026-04-01WuXi AppTec's stock rose 5.03% to 103.03 yuan, with a total market value of 307.4 billion yuan.药明康德股价上涨5.03%，报103.03元，总市值3074.16亿元。
2026-04-28WuXi AppTec's A-share stock hit the daily limit (up 10%) to close at 110.57 yuan, driven by strong Q1 results.药明康德A股涨停，收盘报110.57元，涨幅10%，受强劲一季报推动。
2026-05-01Q1 2026 institutional investors: top 10 holders held 23.29% of shares, down 1.89 pct from prior quarter; 242 public funds increased holdings, 214 decreased.一季度机构投资者：前十大机构持股比例23.29%，较上季下降1.89个百分点；242只公募基金增持，214只减持。
Industry position & policy impact行业地位与政策影响
2 · 2026-05-12 → 2026-05-18
▾
Market share dominance, industry revenue/profit comparisons, and policy changes affecting the CXO sector.市场份额主导地位、行业收入/利润比较及影响CXO行业的政策变化。
2026-05-12National Healthcare Security Administration (NHSA) released 2026 drug catalog adjustment draft, introducing commercial insurance bridge to national医保目录, benefiting innovative drug developers and CXO partners including WuXi AppTec.国家医保局发布2026年药品目录调整征求意见稿，引入商业保险至国家医保目录桥接路径，利好创新药企及CXO合作伙伴包括药明康德。
2026-05-18WuXi AppTec accounted for 48.24% of industry revenue and 76.35% of net profit among top 20 CXO listed companies in Q1 2026, maintaining dominant market share.2026年一季度，药明康德在20家头部CXO上市公司中营收占比48.24%，归母净利润占比76.35%，行业龙头地位稳固。
